<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-journalpublishing1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Pharmaceutics</journal-id><journal-id journal-id-type="iso-abbrev">Pharmaceutics</journal-id><journal-id journal-id-type="publisher-id">pharmaceutics</journal-id><journal-title-group><journal-title>Pharmaceutics</journal-title></journal-title-group><issn pub-type="epub">1999-4923</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6359585</article-id><article-id pub-id-type="doi">10.3390/pharmaceutics11010021</article-id><article-id pub-id-type="publisher-id">pharmaceutics-11-00021</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Microencapsulation and Nanoencapsulation Using Supercritical Fluid (SCF) Techniques</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Soh</surname><given-names>Soon Hong</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-11-00021">1</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Lai Yeng</given-names></name><xref ref-type="aff" rid="af1-pharmaceutics-11-00021">1</xref><xref ref-type="aff" rid="af2-pharmaceutics-11-00021">2</xref><xref rid="c1-pharmaceutics-11-00021" ref-type="corresp">*</xref></contrib></contrib-group><aff id="af1-pharmaceutics-11-00021"><label>1</label>Newcastle Research and Innovation Institute, 80 Jurong East Street 21, #05-04 Devan Nair Institute for Employment &#x00026; Employability, Singapore 609607, Singapore; <email>S.H.Soh1@newcastle.ac.uk</email></aff><aff id="af2-pharmaceutics-11-00021"><label>2</label>Newcastle University in Singapore, 537 Clementi Road, #06-01 SIT Building@Ngee Ann Polytechnic, Singapore 599493, Singapore</aff><author-notes><corresp id="c1-pharmaceutics-11-00021"><label>*</label>Correspondence: <email>laiyeng.lee@ncl.ac.uk</email>; Tel.: +65-6908-6016</corresp></author-notes><pub-date pub-type="epub"><day>05</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2019</year></pub-date><volume>11</volume><issue>1</issue><elocation-id>21</elocation-id><history><date date-type="received"><day>08</day><month>12</month><year>2018</year></date><date date-type="accepted"><day>27</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9; 2019 by the authors.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access"><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>The unique properties of supercritical fluids, in particular supercritical carbon dioxide (CO<sub>2</sub>), provide numerous opportunities for the development of processes for pharmaceutical applications. One of the potential applications for pharmaceuticals includes microencapsulation and nanoencapsulation for drug delivery purposes. Supercritical CO<sub>2</sub> processes allow the design and control of particle size, as well as drug loading by utilizing the tunable properties of supercritical CO<sub>2</sub> at different operating conditions (flow ratio, temperature, pressures, etc.). This review aims to provide a comprehensive overview of the processes and techniques using supercritical fluid processing based on the supercritical properties, the role of supercritical carbon dioxide during the process, and the mechanism of formulation production for each process discussed. The considerations for equipment configurations to achieve the various processes described and the mechanisms behind the representative processes such as RESS (rapid expansion of supercritical solutions), SAS (supercritical antisolvent), SFEE (supercritical fluid extraction of emulsions), PGSS (particles from gas-saturated solutions), drying, and polymer foaming will be explained via schematic representation. More recent developments such as fluidized bed coating using supercritical CO<sub>2</sub> as the fluidizing and drying medium, the supercritical CO<sub>2</sub> spray drying of aqueous solutions, as well as the production of microporous drug releasing devices via foaming, will be highlighted in this review. Development and strategies to control and optimize the particle morphology, drug loading, and yield from the major processes will also be discussed.</p></abstract><kwd-group><kwd>supercritical carbon dioxide</kwd><kwd>microencapsulation</kwd><kwd>microporous foam</kwd><kwd>supercritical drying</kwd><kwd>supercritical anti-solvent</kwd></kwd-group></article-meta></front><body><sec id="sec1-pharmaceutics-11-00021"><title>1. Introduction</title><p>Well-established processes using supercritical CO<sub>2</sub> in pharmaceutical applications include micronization by RESS (rapid expansion of supercritical solutions), SAS (supercritical antisolvent), or ScMM (supercritical melt micronization), microencapsulation via co-precipitation (in RESS, SAS, supercritical spray drying, etc.), active ingredient coating (spray coating, supercritical CO<sub>2</sub> fluid bed coating, etc.), sterilization (due to microbial inactivation properties of pressurized CO<sub>2</sub>), biopolymeric microporous foam/sponges (supercritical foaming, supercritical impregnation, etc.). Many review and research articles have been published on the topic of using supercritical fluid techniques for the development of drug delivery [<xref rid="B1-pharmaceutics-11-00021" ref-type="bibr">1</xref>,<xref rid="B2-pharmaceutics-11-00021" ref-type="bibr">2</xref>,<xref rid="B3-pharmaceutics-11-00021" ref-type="bibr">3</xref>,<xref rid="B4-pharmaceutics-11-00021" ref-type="bibr">4</xref>,<xref rid="B5-pharmaceutics-11-00021" ref-type="bibr">5</xref>,<xref rid="B6-pharmaceutics-11-00021" ref-type="bibr">6</xref>,<xref rid="B7-pharmaceutics-11-00021" ref-type="bibr">7</xref>], biomedical and pharmaceutical formulations or devices [<xref rid="B8-pharmaceutics-11-00021" ref-type="bibr">8</xref>,<xref rid="B9-pharmaceutics-11-00021" ref-type="bibr">9</xref>]. Supercritical fluid can be used in many different ways to produce microencapsulated and nanoencapsulated products based on the properties of the active ingredient, coating material, and suitable solvent (if any) used.</p><p>The selection of processing technique with supercritical CO<sub>2</sub> for biopolymers depend greatly on the interaction of the supercritical CO<sub>2</sub> with the active ingredient, coating material of interest, and suitable solvent. In biopolymeric drug delivery systems, the interaction of the polymer with supercritical CO<sub>2</sub> plays an important role in the selection of the supercritical process. For instance, polylactide (PLA) is a suitable candidate for SAS, but not RESS, as it is not easily soluble in supercritical CO<sub>2</sub> [<xref rid="B10-pharmaceutics-11-00021" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-11-00021" ref-type="bibr">11</xref>]. On the other hand, polylactide-<italic>co</italic>-glycolide (PLGA) has a low glass transition temperature (<italic>T</italic><sub>g</sub>), and the further depression of its <italic>T</italic><sub>g</sub> in the presence of supercritical CO<sub>2</sub> makes it difficult to produce discrete free-flowing powders via the SAS process. However, this property of PLGA makes it suitable for the production of microporous polymeric foams with very low residual organic solvent content, allowing the production of microporous drug-releasing polymeric foams that can be used as implant and scaffold material [<xref rid="B12-pharmaceutics-11-00021" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-11-00021" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-11-00021" ref-type="bibr">14</xref>].</p><p>Well-established methods for drug microencapsulation and nanoencapsulation for drug delivery include solvent evaporation, emulsion techniques, spray drying, and electrospray. Due to its attractive properties as a clean and green solvent for processing drugs and biopolymers, supercritical CO<sub>2</sub> processing has been regarded as an important option for the production of microencapsulated drug delivery devices [<xref rid="B15-pharmaceutics-11-00021" ref-type="bibr">15</xref>].</p><p>The role of supercritical CO<sub>2</sub> (as a solvent, antisolvent, or solute) in particle design, pharmaceutical ingredient processing, and composite particle production has been evaluated by earlier reviews [<xref rid="B6-pharmaceutics-11-00021" ref-type="bibr">6</xref>,<xref rid="B9-pharmaceutics-11-00021" ref-type="bibr">9</xref>,<xref rid="B16-pharmaceutics-11-00021" ref-type="bibr">16</xref>,<xref rid="B17-pharmaceutics-11-00021" ref-type="bibr">17</xref>,<xref rid="B18-pharmaceutics-11-00021" ref-type="bibr">18</xref>]. In a more recent review by Padrela et al. [<xref rid="B19-pharmaceutics-11-00021" ref-type="bibr">19</xref>], the production of nanoparticle and nanocrystals via supercritical carbon dioxide was evaluated with a comprehensive description of the selection criteria of different methods based on the properties of the active ingredient. This review will focus on the applications where the active ingredient is encapsulated in microsized, nanosized, or microstructured formulations with applications for pharmaceutical or drug delivery. This paper aims to provide the reader with a comprehensive review of the currently available options to design and produce microencapsulated and nanoencapsulated formulations ranging from microparticles to nanoparticles, and including recent developments such as fluidized bed coating using supercritical CO<sub>2</sub> and the production of drug-releasing three-dimensional microporous foam for pharmaceutical applications. The discussion will introduce readers to different supercritical fluid processing techniques that utilize the favorable and versatile properties displayed by supercritical CO<sub>2</sub>, with an understanding of the underlying mechanism behind each method, and the modifications applied to improve the particle size, morphology, and process efficiency.</p></sec><sec id="sec2-pharmaceutics-11-00021"><title>2. Supercritical Carbon Dioxide Processing Systems</title><p>Depending on the active ingredient or drug compound of interest, the type of formulation required (e.g., selection of suitable coating material for desired release profile), and the morphology of the final encapsulated product, it is possible to modify the configuration of the supercritical fluid system to perform different processes, as shown in our earlier studies where experiments for SAS [<xref rid="B10-pharmaceutics-11-00021" ref-type="bibr">10</xref>,<xref rid="B11-pharmaceutics-11-00021" ref-type="bibr">11</xref>,<xref rid="B20-pharmaceutics-11-00021" ref-type="bibr">20</xref>], SAS with enhanced mass transfer (SAS-EM) [<xref rid="B10-pharmaceutics-11-00021" ref-type="bibr">10</xref>], supercritical foaming [<xref rid="B12-pharmaceutics-11-00021" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-11-00021" ref-type="bibr">13</xref>,<xref rid="B14-pharmaceutics-11-00021" ref-type="bibr">14</xref>,<xref rid="B21-pharmaceutics-11-00021" ref-type="bibr">21</xref>], and supercritical drying [<xref rid="B22-pharmaceutics-11-00021" ref-type="bibr">22</xref>] were performed with a custom-built supercritical fluid system.</p><p>The main sections for a supercritical CO<sub>2</sub> unit for drug delivery production include: (i) a high-pressure CO<sub>2</sub> delivery system; (ii) a secondary high-pressure delivery system; (iii) a high-pressure vessel(s)/high-pressure chamber(s); (iv) a product separation/collection/purification system. The basic equipment required for supercritical CO<sub>2</sub> processing include: (1) a compressed liquid CO<sub>2</sub> cylinder (preferably with a dipstick); (2) high-pressure liquid pumps for the delivery of CO<sub>2</sub> to supercritical pressure, and for co-solvents or solutions to be delivered and in contact with high-pressure CO<sub>2</sub>; (3) chillers for liquefying, or ensuring that the CO<sub>2</sub> at the pump head is in a liquid state; (4) high-pressure chambers/vessels that need to be designed according to specifications of high-pressure vessels with fittings and tubings rated for high-pressure applications (from HIP, Swagelok etc.); (5) pressure controllers (either automated back-pressure regulators or back-pressure valves; (6) product separation units, such as flash vessels, cyclone separators for solid&#x02013;fluid separation, solid filter units, a zeolite-packed bed for removing moisture from water-saturated supercritical CO<sub>2</sub>; (7) heaters/coolers for temperature control at various stages of the process, and (8) a recirculating pump (if the CO<sub>2</sub> is recycled). A detailed summary of supercritical fluid particle formation in the pharmaceutical industry and representative vendor for supercritical fluid equipment and accessories can be found in the work of Vemavarapu et al. [<xref rid="B23-pharmaceutics-11-00021" ref-type="bibr">23</xref>].</p></sec><sec id="sec3-pharmaceutics-11-00021"><title>3. Role of Supercritical Carbon Dioxide in Microencapsulation and Nanoencapsulation</title><p>CO<sub>2</sub> has relatively accessible critical conditions of 73.8 bar and 31.1 &#x000b0;C. Its low critical temperature allows processes to be developed at close to ambient temperatures (e.g., at 35 &#x000b0;C). Other favorable qualities of supercritical CO<sub>2</sub> include its non-toxic and non-flammable nature, gas-like viscosity, liquid-like density with enhanced solubility, microbial inactivation abilities, and relatively low cost. <xref ref-type="fig" rid="pharmaceutics-11-00021-f001">Figure 1</xref> summarizes the properties of supercritical CO<sub>2</sub>, which allow it to be applied for various microencapsulation and nanoencapsulation processes. The selection of the processing techniques used for microencapsulation and nanoencapsulation depends on the materials and thermodynamic properties of the active ingredient, the coating material, and any suitable co-solvent that is available. Other criteria in the selection of a suitable supercritical fluid technique include the desired formulation (size, morphology, release profiles, porosity, etc.).</p><p>The role of supercritical CO<sub>2</sub> as a solvent, antisolvent, solute, drying medium, and foaming agent will be evaluated and explained in the following sections.</p><sec id="sec3dot1-pharmaceutics-11-00021"><title>3.1. Supercritical Carbon Dioxide as a Solvent</title><p>At supercritical conditions, CO<sub>2</sub> has enhanced solubility for substances such as essential oils, active ingredients in plants and natural products [<xref rid="B24-pharmaceutics-11-00021" ref-type="bibr">24</xref>,<xref rid="B25-pharmaceutics-11-00021" ref-type="bibr">25</xref>,<xref rid="B26-pharmaceutics-11-00021" ref-type="bibr">26</xref>], small molecular weight non-polar compounds, and low-molecular weight biopolymers. As supercritical conditions can be reached even at low temperature, this makes supercritical CO<sub>2</sub> very attractive as a solvent, and it has been applied in numerous studies for the extraction of active ingredients (e.g., for caffeine decaffeination, essential oil extraction, active ingredient encapsulation, etc.).</p><sec><title>Rapid Expansion of Supercritical Solutions (RESS)</title><p>In the rapid expansion of supercritical solutions (RESS), the active ingredient and coating ingredient are dissolved in a supercritical fluid (acting as a solvent). The supercritical fluid solution containing the solutes is maintained at high pressure before expanding across a fine throttling device, such as a capillary or orifice nozzle [<xref rid="B27-pharmaceutics-11-00021" ref-type="bibr">27</xref>,<xref rid="B28-pharmaceutics-11-00021" ref-type="bibr">28</xref>,<xref rid="B29-pharmaceutics-11-00021" ref-type="bibr">29</xref>]. At this point, supersaturation occurs, leading to the desolvation of the coating material, which is then deposited around the active ingredient, forming microcapsules (<xref ref-type="fig" rid="pharmaceutics-11-00021-f002">Figure 2</xref>). In active pharmaceutical ingredient (API) encapsulation applications, the microcrystalline pharmaceutical dominates the core of the particles, while the slower precipitating polymer coats the surface. The advantages of RESS include its capacity for a wide range of inorganic, organic, and polymeric materials, low-temperature operation, and single-step processing [<xref rid="B30-pharmaceutics-11-00021" ref-type="bibr">30</xref>]. <xref rid="pharmaceutics-11-00021-t001" ref-type="table">Table 1</xref> shows some examples of bioproducts that are encapsulated using the RESS process. The prerequisite of this process is that both the active ingredient and the coating material must be very soluble in supercritical fluids. This typically applies to lower molecular weight polymers and small active ingredients such as non-polar small molecule compounds.</p><p>The RESS of polymer solutions in CO<sub>2</sub> has been limited by low polymer solubility at temperatures below 80 &#x000b0;C [<xref rid="B31-pharmaceutics-11-00021" ref-type="bibr">31</xref>]. To overcome this limitation, the RESS process can be modified with the application of a co-solvent. The solubility of the polymers in CO<sub>2</sub> increases significantly with low molecular weight alcohols as co-solvents, such as ethanol and methanol [<xref rid="B32-pharmaceutics-11-00021" ref-type="bibr">32</xref>]. The modified process is termed as rapid expansion of supercritical solutions with a non-solvent (RESS-N). In the RESS-N process, a suspension of the active ingredient in a co-solvent containing CO<sub>2</sub> and a dissolved polymer is sprayed through a nozzle to atmospheric pressure. The co-solvent, in pure form, is a non-solvent for the polymer, and is only sparingly soluble in the polymer particles that are produced during expansion [<xref rid="B33-pharmaceutics-11-00021" ref-type="bibr">33</xref>]. Therefore, the particles do not agglomerate after expansion, since there is no swelling of polymer products. The modified RESS has been applied to the encapsulation of proteins [<xref rid="B32-pharmaceutics-11-00021" ref-type="bibr">32</xref>] and medicines [<xref rid="B34-pharmaceutics-11-00021" ref-type="bibr">34</xref>], as shown in <xref rid="pharmaceutics-11-00021-t002" ref-type="table">Table 2</xref>. The polymer-coating thickness, mean particle diameter, and particle size distribution of microcapsules could be controlled by changing the feed composition of the polymer [<xref rid="B32-pharmaceutics-11-00021" ref-type="bibr">32</xref>,<xref rid="B34-pharmaceutics-11-00021" ref-type="bibr">34</xref>].</p></sec></sec><sec id="sec3dot2-pharmaceutics-11-00021"><title>3.2. Supercritical Carbon Dioxide as an Anti-Solvent</title><p>The limitations of RESS can be overcome by a supercritical antisolvent (SAS), which utilizes the high miscibility of supercritical CO<sub>2</sub> with organic solvents; this can be used to dissolve both the active ingredient and the coating material of interest. When the organic solution is introduced into supercritical CO<sub>2</sub>, the CO<sub>2</sub> rapidly extracts the organic solvent from the solution jet, leading to the rapid precipitation of the composite product. The resulting product will be an active ingredient distributed in the matrix of the coating material.</p><sec id="sec3dot2dot1-pharmaceutics-11-00021"><title>3.2.1. Supercritical Antisolvent (SAS)</title><p>The supercritical antisolvent (SAS) technique is one of the most versatile [<xref rid="B35-pharmaceutics-11-00021" ref-type="bibr">35</xref>] and widely researched techniques using supercritical CO<sub>2</sub> for micronization and microencapsulation [<xref rid="B10-pharmaceutics-11-00021" ref-type="bibr">10</xref>,<xref rid="B35-pharmaceutics-11-00021" ref-type="bibr">35</xref>,<xref rid="B36-pharmaceutics-11-00021" ref-type="bibr">36</xref>,<xref rid="B37-pharmaceutics-11-00021" ref-type="bibr">37</xref>,<xref rid="B38-pharmaceutics-11-00021" ref-type="bibr">38</xref>,<xref rid="B39-pharmaceutics-11-00021" ref-type="bibr">39</xref>,<xref rid="B40-pharmaceutics-11-00021" ref-type="bibr">40</xref>,<xref rid="B41-pharmaceutics-11-00021" ref-type="bibr">41</xref>,<xref rid="B42-pharmaceutics-11-00021" ref-type="bibr">42</xref>,<xref rid="B43-pharmaceutics-11-00021" ref-type="bibr">43</xref>,<xref rid="B44-pharmaceutics-11-00021" ref-type="bibr">44</xref>,<xref rid="B45-pharmaceutics-11-00021" ref-type="bibr">45</xref>,<xref rid="B46-pharmaceutics-11-00021" ref-type="bibr">46</xref>,<xref rid="B47-pharmaceutics-11-00021" ref-type="bibr">47</xref>,<xref rid="B48-pharmaceutics-11-00021" ref-type="bibr">48</xref>,<xref rid="B49-pharmaceutics-11-00021" ref-type="bibr">49</xref>,<xref rid="B50-pharmaceutics-11-00021" ref-type="bibr">50</xref>,<xref rid="B51-pharmaceutics-11-00021" ref-type="bibr">51</xref>,<xref rid="B52-pharmaceutics-11-00021" ref-type="bibr">52</xref>]. The process can be applied to a wide range of compounds and biopolymers that have limited solubility in supercritical CO<sub>2</sub>. The SAS process has been applied in micronizing APIs, and has been shown to produce improve bioavailability and the solubility of hydrophobic drug compounds by size reduction and the control of crystal morphology [<xref rid="B41-pharmaceutics-11-00021" ref-type="bibr">41</xref>]. Different biopolymeric morphologies (threads, sponges, and microparticles) can also be achieved from SAS processes [<xref rid="B49-pharmaceutics-11-00021" ref-type="bibr">49</xref>]. Although the SAS is favorable for the production of formulations for hydrophobic drugs with low bioavailability and poor aqueous solubility [<xref rid="B41-pharmaceutics-11-00021" ref-type="bibr">41</xref>,<xref rid="B44-pharmaceutics-11-00021" ref-type="bibr">44</xref>,<xref rid="B47-pharmaceutics-11-00021" ref-type="bibr">47</xref>,<xref rid="B53-pharmaceutics-11-00021" ref-type="bibr">53</xref>], the encapsulation of hydrophilic compounds [<xref rid="B40-pharmaceutics-11-00021" ref-type="bibr">40</xref>,<xref rid="B54-pharmaceutics-11-00021" ref-type="bibr">54</xref>] have also been demonstrated by dispersing the hydrophilic drug in the organic solution. The co-precipitation produces monolithic matrix systems rather than reservoir systems, and the drug release profiles typically follow diffusion-controlled or polymer degradation mechanisms [<xref rid="B10-pharmaceutics-11-00021" ref-type="bibr">10</xref>].</p><p>Typically, SAS operates by the continuous and simultaneous injection of the organic solution with supercritical CO<sub>2</sub> into a chamber with supercritical CO<sub>2</sub> via a nozzle. The mechanism of particle formation using SAS is illustrated in <xref ref-type="fig" rid="pharmaceutics-11-00021-f003">Figure 3</xref>. The means of contact between the solution and CO<sub>2</sub> can vary in different versions of the process, leading to several variations in the SAS process such as the PCA (precipitation from compressed antisolvent) [<xref rid="B55-pharmaceutics-11-00021" ref-type="bibr">55</xref>], ASES (aerosol solvent extraction system) [<xref rid="B50-pharmaceutics-11-00021" ref-type="bibr">50</xref>], SEDS (solution-enhanced dispersion by supercritical fluids) [<xref rid="B42-pharmaceutics-11-00021" ref-type="bibr">42</xref>], and SAA (supercritical-assisted atomization) [<xref rid="B53-pharmaceutics-11-00021" ref-type="bibr">53</xref>]. In the SEDS process, the solution and supercritical CO<sub>2</sub> were introduced into the precipitation vessel simultaneously via a co-axial nozzle. This enhanced the dispersion and contact between the solution and supercritical CO<sub>2</sub>. Chattopadhyay and Gupta [<xref rid="B56-pharmaceutics-11-00021" ref-type="bibr">56</xref>] designed a method of combining ultrasonic mixing within a SAS chamber to achieve nanoparticle and nanoencapsulations [<xref rid="B54-pharmaceutics-11-00021" ref-type="bibr">54</xref>] via an enhanced mixing mechanism between supercritical CO<sub>2</sub> and the organic solution. These processes were designed and developed to achieve better understanding and control of the SAS process in order to obtain particles with desired characteristics [<xref rid="B43-pharmaceutics-11-00021" ref-type="bibr">43</xref>,<xref rid="B48-pharmaceutics-11-00021" ref-type="bibr">48</xref>,<xref rid="B57-pharmaceutics-11-00021" ref-type="bibr">57</xref>]. In addition, numerous studies were also carried out to understand the underlying mechanism during SAS, such as the jet break-up phenomena [<xref rid="B10-pharmaceutics-11-00021" ref-type="bibr">10</xref>,<xref rid="B20-pharmaceutics-11-00021" ref-type="bibr">20</xref>,<xref rid="B58-pharmaceutics-11-00021" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceutics-11-00021" ref-type="bibr">59</xref>], the role of mass transfer [<xref rid="B46-pharmaceutics-11-00021" ref-type="bibr">46</xref>,<xref rid="B56-pharmaceutics-11-00021" ref-type="bibr">56</xref>], the solvent&#x02013;antisolvent interaction behavior, etc.</p></sec><sec id="sec3dot2dot2-pharmaceutics-11-00021"><title>3.2.2. Supercritical Fluidized Bed Coating</title><p>Fluidized bed drying and coating processes have been well established as scalable means of obtaining coated APIs (e.g., Wurster fluid bed coating) [<xref rid="B60-pharmaceutics-11-00021" ref-type="bibr">60</xref>]. The use of supercritical CO<sub>2</sub> as the fluidizing medium for core particles as well as the drying agent or antisolvent to remove the moisture or solvent respectively from core particles coated with the coating material solution is of great interest, as it allows the coating to be performed in oxygen-free and low-temperature conditions.</p><p>In the studies by Subramaniam et al. [<xref rid="B61-pharmaceutics-11-00021" ref-type="bibr">61</xref>], a Wurster-type coater employing near-critical CO<sub>2</sub> as an antisolvent for solvent removal from coated particles was developed. Studies on particle fluidization with supercritical CO<sub>2</sub> have shown that conventional correlations for fluidization can be applied for supercritical fluids for the prediction of minimum fluidizing and terminal velocities [<xref rid="B62-pharmaceutics-11-00021" ref-type="bibr">62</xref>]. Supercritical fluidized bed coating utilizes the fluidization of solid core particles using supercritical CO<sub>2</sub> as a fluidizing medium and at the same time, a solution with the coating material will be sprayed onto the fluidized particles. The supercritical CO<sub>2</sub> plays the role of a drying medium (for aqueous solutions) or an antisolvent (for organic solutions) to dry the fluidized particles in the bed. The coating of API and ingredients such as curcumin has been demonstrated using supercritical fluid coating processes [<xref rid="B61-pharmaceutics-11-00021" ref-type="bibr">61</xref>,<xref rid="B63-pharmaceutics-11-00021" ref-type="bibr">63</xref>,<xref rid="B64-pharmaceutics-11-00021" ref-type="bibr">64</xref>,<xref rid="B65-pharmaceutics-11-00021" ref-type="bibr">65</xref>]. This technique has promising development for the production of controlled multi-layered coatings on APIs to achieve formulations with desired sustained release or surface properties.</p></sec><sec id="sec3dot2dot3-pharmaceutics-11-00021"><title>3.2.3. Supercritical Fluid Extraction of Emulsions (SFEE)</title><p>One of the limitations of RESS and SAS in microencapsulation is the processing of polymers that tend to plasticize in the presence of supercritical CO<sub>2</sub>, including the class of commonly used amorphous polymers in drug delivery (including PLGA, polymethylmethacrylate (PMMA), and polycaprolactone (PCL)) [<xref rid="B66-pharmaceutics-11-00021" ref-type="bibr">66</xref>]. To overcome the above-mentioned limitations, Chattopadhyay and Shekunov [<xref rid="B66-pharmaceutics-11-00021" ref-type="bibr">66</xref>] presented the supercritical fluid extraction of emulsions (SFEE) technique. In this technique, the active ingredient and polymer is dissolved in organic solvent, and the organic phase and the organic solution are then emulsified with aqueous phase to form an oil/water emulsion. Supercritical CO<sub>2</sub> is used to extract the organic solvent from the emulsion, leading to the supersaturation of the active ingredient and polymer in the aqueous phase, and resulting in the precipitation of the active ingredient and polymer. The precipitated microencapsulation or nanoencapsulation particles are subsequently collected from the aqueous phase. <xref ref-type="fig" rid="pharmaceutics-11-00021-f004">Figure 4</xref> illustrates the general schematic representation of the SFEE process.</p><p>An important feature of the SFEE process is the ability to form nearly monodisperse microencapsulates or nanoencapsulates. <xref rid="pharmaceutics-11-00021-t003" ref-type="table">Table 3</xref> shows examples of microencapsulated and nanoencapsulated formulations produced using the SFEE process. Active ingredients ranging from low-bioavailability hydrophobic drugs [<xref rid="B66-pharmaceutics-11-00021" ref-type="bibr">66</xref>,<xref rid="B67-pharmaceutics-11-00021" ref-type="bibr">67</xref>,<xref rid="B68-pharmaceutics-11-00021" ref-type="bibr">68</xref>] to model proteins [<xref rid="B69-pharmaceutics-11-00021" ref-type="bibr">69</xref>] and even oils [<xref rid="B70-pharmaceutics-11-00021" ref-type="bibr">70</xref>] can be encapsulated using this method.</p></sec></sec><sec id="sec3dot3-pharmaceutics-11-00021"><title>3.3. Supercritical Carbon Dioxide as a Drying Agent</title><p>CO<sub>2</sub> has an increased affinity for water at conditions above its critical point (31.1 &#x000b0;C, 73.8 bar) [<xref rid="B73-pharmaceutics-11-00021" ref-type="bibr">73</xref>], which makes it a good candidate for drying aqueous solutions and wet samples that otherwise cannot be dried by traditional drying techniques due to their thermal sensitivity and oxidation. Supercritical CO<sub>2</sub> has been found to be a good drying medium for food matrices [<xref rid="B74-pharmaceutics-11-00021" ref-type="bibr">74</xref>,<xref rid="B75-pharmaceutics-11-00021" ref-type="bibr">75</xref>,<xref rid="B76-pharmaceutics-11-00021" ref-type="bibr">76</xref>,<xref rid="B77-pharmaceutics-11-00021" ref-type="bibr">77</xref>], aerogels [<xref rid="B78-pharmaceutics-11-00021" ref-type="bibr">78</xref>,<xref rid="B79-pharmaceutics-11-00021" ref-type="bibr">79</xref>,<xref rid="B80-pharmaceutics-11-00021" ref-type="bibr">80</xref>,<xref rid="B81-pharmaceutics-11-00021" ref-type="bibr">81</xref>,<xref rid="B82-pharmaceutics-11-00021" ref-type="bibr">82</xref>], and other natural products [<xref rid="B22-pharmaceutics-11-00021" ref-type="bibr">22</xref>] due to its offer of low processing temperatures.</p><sec><title>Supercritical Spray Drying </title><p>Supercritical spray drying refers to the spraying of an aqueous solution into an excess of supercritical CO<sub>2</sub>. Similar to hot air spray-drying, supercritical CO<sub>2</sub> spray drying utilizes the increased solubility of CO<sub>2</sub> with water at supercritical conditions. The break-up of the aqueous solution into very tiny droplets (with high surface area to volume ratios) enhances the mass transfer of water into the supercritical CO<sub>2</sub> in the drying chamber and therefore, the water is removed continually from the drying chamber. <xref ref-type="fig" rid="pharmaceutics-11-00021-f005">Figure 5</xref> shows the schematic representation of the supercritical spray-drying process.</p><p>This technique is suitable in the microencapsulation formulations where the coating material is a water-soluble material (such as sugars, starches, maltodextrin, etc.), which will form the aqueous phase that will be sprayed into supercritical CO<sub>2</sub>. The active ingredient can be dissolved in the same aqueous phase (proteins or hydrophilic compounds) or distributed in the aqueous phase via emulsification (oil, fatty acids, or organic solution) or suspension (fine solid particles). One promising application of the process is the encapsulation of oils to produce free-flowing oil encapsulated powders [<xref rid="B51-pharmaceutics-11-00021" ref-type="bibr">51</xref>,<xref rid="B83-pharmaceutics-11-00021" ref-type="bibr">83</xref>,<xref rid="B84-pharmaceutics-11-00021" ref-type="bibr">84</xref>,<xref rid="B85-pharmaceutics-11-00021" ref-type="bibr">85</xref>], which can be applied in the nutraceutical market for oil (polyunsaturated fatty acids (PUFAs), docosahexaenoic acids (DHAs), eicosapentaenoic acid (EPAs) etc.). The production of a water-insoluble phospholipid-rich oil has been reported in the World Intellectual Property Organization (WO) patent application (WO 2010014011 A1) [<xref rid="B86-pharmaceutics-11-00021" ref-type="bibr">86</xref>], where a two-step supercritical spray drying followed by a supercritical antisolvent procedure (for coating) was performed to obtain a microencapsulated oil with a non-soluble coating. Units ranging from four liters to 10 liters have been developed for the laboratory to demonstration scale of supercritical spray drying, where a co-axial nozzle was used to introduce and break up the aqueous solution into finely dispersed droplets using scCO<sub>2</sub> as the dispersing agent and drying medium [<xref rid="B87-pharmaceutics-11-00021" ref-type="bibr">87</xref>].</p></sec></sec><sec id="sec3dot4-pharmaceutics-11-00021"><title>3.4. Supercritical Carbon Dioxide as a Solute</title><p>Due to its low viscosity and high diffusivity, supercritical CO<sub>2</sub> can diffuse very efficiently into solutions, polymer melts, and also fatty acids. Using this property of supercritical CO<sub>2</sub>, strategies for producing microencapsulated particles from an aqueous solution can be achieved.</p><sec><title>Particles from Gas-Saturated Solutions (PGSS)</title><p>In particles from gas-saturated solutions (PGSS), supercritical CO<sub>2</sub> acts as a solute, diffusing and dissolving into a melt or solution, forming a gas-saturated solution. The solution will then be expanded via a nozzle into a spray chamber at atmospheric pressure. The CO<sub>2</sub> gas then leaves the gas-saturated polymer/fat droplets and also during expansion, the temperature of the mixture reduces drastically due to the Joule&#x02013;Thomson effect, hence causing the polymer solidification [<xref rid="B88-pharmaceutics-11-00021" ref-type="bibr">88</xref>]. A similar process termed as supercritical melt micronization (ScMM) has been developed for the micronization of fats (such as hard fats or milk fats) [<xref rid="B89-pharmaceutics-11-00021" ref-type="bibr">89</xref>,<xref rid="B90-pharmaceutics-11-00021" ref-type="bibr">90</xref>,<xref rid="B91-pharmaceutics-11-00021" ref-type="bibr">91</xref>,<xref rid="B92-pharmaceutics-11-00021" ref-type="bibr">92</xref>]. For microencapsulation application, the PGSS process can be used for water-soluble active ingredients and coating materials. The PGSS drying process (<xref ref-type="fig" rid="pharmaceutics-11-00021-f006">Figure 6</xref>) involves mixing an aqueous solution, containing the active material and wall material, and saturating the solution with supercritical CO<sub>2</sub>. Subsequently, the gas-saturated solution is expanded via a nozzle into a spray chamber at atmospheric pressure. This leads to the encapsulation of key compounds by the co-precipitation of the coating and core materials. PGSS holds several advantages over conventional methods such as coacervation, spray-drying, and emulsion techniques due to its mild operating conditions and its ability to produce solvent-free and homogenous products. This is especially beneficial in preserving the stability of ingredients such as essential oils [<xref rid="B93-pharmaceutics-11-00021" ref-type="bibr">93</xref>,<xref rid="B94-pharmaceutics-11-00021" ref-type="bibr">94</xref>] and heat-sensitive virus proteins [<xref rid="B95-pharmaceutics-11-00021" ref-type="bibr">95</xref>], where elevated temperatures and organic solvents could cause negative interactions. <xref rid="pharmaceutics-11-00021-t004" ref-type="table">Table 4</xref> shows examples of bioproducts encapsulated via PGSS.</p></sec></sec><sec id="sec3dot5-pharmaceutics-11-00021"><title>3.5. Supercritical CO<sub>2</sub> as a Foaming Agent</title><p>In the production of microporous biopolymeric structures via supercritical CO<sub>2</sub> foaming, supercritical CO<sub>2</sub> is first contacted with the polymer in a high-pressure chamber. The supercritical CO<sub>2</sub> diffuses into the polymer matrix, causing the glass transition temperature (<italic>T</italic><sub>g</sub>) of the polymer to be lowered, and forming a solution of the polymer with CO<sub>2</sub>. On depressurization, the CO<sub>2</sub> leaves the polymer&#x02013;CO<sub>2</sub> mixture and the polymer vitrify, leaving a microporous structure on the polymer. In this case, CO<sub>2</sub> actually acts both as a solute and a foaming agent. This section will focus of the role of CO<sub>2</sub> as a foaming agent to produce the microporous structure within the biopolymer matrix as a potential drug delivery platform for pharmaceutical applications.</p><p>The supercritical CO<sub>2</sub> foaming of biopolymers is an attractive method for the production of microporous constructs for biomedical applications. Using supercritical carbon dioxide as a foaming agent, the use of organic solvents for the fabrication of the PLGA foams can be minimized or avoided, resulting in a zero to low-residual solvent product. The pore size and morphology of the PLGA foams can be controlled by factors such as the operating conditions of the foaming process (temperature, pressure), the rate of depressurization, and the nature of the selected co-polymer (polymer functional end groups, lactic to glycolic ratio, molecular weight, etc.). The encapsulation of active ingredients ranging from protein, anticancer drugs, chitosan, etc. has been demonstrated for potential applications for implant drug delivery for chemotherapy, scaffold material for cell cultivation, new carriers for DNA delivery, etc.</p><p>Strategies for encapsulating the active ingredient or drug in a microporous biopolymeric matrix include a single-step impregnation process, as presented by Cabezas et al. [<xref rid="B102-pharmaceutics-11-00021" ref-type="bibr">102</xref>,<xref rid="B103-pharmaceutics-11-00021" ref-type="bibr">103</xref>] and via a two-step encapsulation supercritical foaming process [<xref rid="B12-pharmaceutics-11-00021" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-11-00021" ref-type="bibr">13</xref>]. The supercritical foaming of biodegradable polymers such as polylactic-<italic>co</italic>-glycolic acid (PLGA) has potential applications for drug delivery and biomedical implants.</p><sec id="sec3dot5dot1-pharmaceutics-11-00021"><title>3.5.1. Single-Step Impregnation and Foaming</title><p>In the single-step impregnation and foaming process to produce microporous biopolymeric foams with encapsulated ingredients, supercritical CO<sub>2</sub> acts both as a solvent for the active ingredient and as a solute in infiltrating the polymer matrix. This is a promising technique where a residual solvent-free implant can be obtained at low processing temperatures, which can be particularly important for thermally-labile active ingredients [<xref rid="B104-pharmaceutics-11-00021" ref-type="bibr">104</xref>]. Indomethacin [<xref rid="B103-pharmaceutics-11-00021" ref-type="bibr">103</xref>] and 5-fluorouracil [<xref rid="B102-pharmaceutics-11-00021" ref-type="bibr">102</xref>] have been encapsulated in microporous polymer foams using the impregnation and foaming processes.</p><p>One of the current limitations of this method is that the drug loading in the polymeric material is limited by the solubility of the solute in the supercritical CO<sub>2</sub>. To achieve higher drug loading and encapsulation efficiencies, and to be able to encapsulate a range of different active ingredients (hydrophobic, hydrophilic, etc.), a two-step process can be considered for the design of desired formulations.</p></sec><sec id="sec3dot5dot2-pharmaceutics-11-00021"><title>3.5.2. Two-Step Drug Encapsulation and Foaming </title><p>The two-step process of drug encapsulation and foaming involves first obtaining a drug-encapsulated polymer matrix via methods such as solvent casting [<xref rid="B105-pharmaceutics-11-00021" ref-type="bibr">105</xref>], spray drying [<xref rid="B12-pharmaceutics-11-00021" ref-type="bibr">12</xref>,<xref rid="B13-pharmaceutics-11-00021" ref-type="bibr">13</xref>], or emulsion methods [<xref rid="B21-pharmaceutics-11-00021" ref-type="bibr">21</xref>]. The drug-encapsulated polymer then undergoes supercritical gas foaming to obtain a microporous polymeric structure with the drug encapsulated in the polymer matrix. The encapsulation of the active ingredient in the polymer matrix is not limited by its solubility in supercritical CO<sub>2</sub>, as the precursor drug-loaded polymer can be achieved by other well-established encapsulation methods such as solvent evaporation, emulsification methods, or spray drying (<xref ref-type="fig" rid="pharmaceutics-11-00021-f007">Figure 7</xref>).</p><p>In this method, most of the drug encapsulated in the polymer prior to foaming will remain in the microporous foamed product [<xref rid="B12-pharmaceutics-11-00021" ref-type="bibr">12</xref>,<xref rid="B21-pharmaceutics-11-00021" ref-type="bibr">21</xref>]. One drawback of the two-step encapsulation and foaming process is that an organic solvent is typically used in the first step. However, as CO<sub>2</sub> is able to penetrate into the polymer matrix, the residual solvent is also removed by the CO<sub>2</sub> during the foaming process, leaving behind a product with very low residual solvent content [<xref rid="B12-pharmaceutics-11-00021" ref-type="bibr">12</xref>]. In our earlier studies, it was observed that the residual solvent in spray-dried particles of paclitaxel-loaded PLGA (using dichloromethane as the solvent) is reduced significantly after the CO<sub>2</sub> foaming process [<xref rid="B12-pharmaceutics-11-00021" ref-type="bibr">12</xref>]. Formulations encapsulating chitosan [<xref rid="B13-pharmaceutics-11-00021" ref-type="bibr">13</xref>], paclitaxel [<xref rid="B12-pharmaceutics-11-00021" ref-type="bibr">12</xref>], curcumin, and gentamicin [<xref rid="B21-pharmaceutics-11-00021" ref-type="bibr">21</xref>] for applications as implants or scaffolds have been demonstrated using this method. The active ingredient will be encapsulated within the matrix of the microporous structure, and drug release will follow a diffusion mechanism and/or follow the degradation of the polymer matrix [<xref rid="B12-pharmaceutics-11-00021" ref-type="bibr">12</xref>,<xref rid="B106-pharmaceutics-11-00021" ref-type="bibr">106</xref>]. The microporous structure as a drug delivery device is particularly useful for the delivery of drugs with low bioavailability and low solubility. The high surface to volume ratio of the formulation enhances the drug release by diffusion [<xref rid="B12-pharmaceutics-11-00021" ref-type="bibr">12</xref>,<xref rid="B106-pharmaceutics-11-00021" ref-type="bibr">106</xref>].</p></sec></sec></sec><sec id="sec4-pharmaceutics-11-00021"><title>4. Conclusions and Future Perspectives</title><p>The favorable and tunable properties of supercritical CO<sub>2</sub> make it a very attractive option in processing products for pharmaceutical applications, particularly regarding the microencapsulation and nanoencapsulation of drugs or active ingredients for sustained or targeted release. The process that is selected depends on the properties of the active ingredient and coating material of interest, such as the solubility, hydrophobicity, molecular weight, glass transition temperatures, crystallinity, etc. The SAS method is very useful in the micronization and formation of amorphous drug particles. However, not all biopolymers can be processed using SAS due to the interaction of supercritical CO<sub>2</sub> with the polymer. The SFEE technique provides an elegant alternative to the SAS process, which can be used to process a wider range of drug delivery polymers such as PCL, PLGA, PHBV, etc. Recent developments in combining a fluidization coating with SAS or supercritical drying also offer opportunities for the more specific design of a controlled-release formulation. The supercritical foaming technique allows three-dimensional microporous polymeric structures with encapsulated drugs to be produced. This provides opportunities to develop controlled release scaffold or implant materials.</p><p>The versatility and compatibility of supercritical fluid processing techniques also allow smart coating materials such as cyclodextrins to be used as encapsulating agents, which is useful in the nanoencapsulation and microencapsulation of flavors and aromas [<xref rid="B107-pharmaceutics-11-00021" ref-type="bibr">107</xref>,<xref rid="B108-pharmaceutics-11-00021" ref-type="bibr">108</xref>,<xref rid="B109-pharmaceutics-11-00021" ref-type="bibr">109</xref>,<xref rid="B110-pharmaceutics-11-00021" ref-type="bibr">110</xref>,<xref rid="B111-pharmaceutics-11-00021" ref-type="bibr">111</xref>]. Formulations with cyclodextrins can also be produced for drug delivery applications, as demonstrated by Adeoye et al. for ibuprofen/hydroxypropyl-&#x003b3;-cyclodextrin inclusion complexes via a supercritical CO<sub>2</sub>-assisted spray-drying process [<xref rid="B112-pharmaceutics-11-00021" ref-type="bibr">112</xref>]. In our opinion, it will be important to develop integrated supercritical CO<sub>2</sub> processing strategies that combine multiple steps in pharmaceutical processing. The highly tunable solvent properties of supercritical CO<sub>2</sub> can be explored to develop processes for particle formation or encapsulation, the removal of impurities and residual solvents, and the separation and recovery of organic solvents in a single process train, which can help intensify the pharmaceutical production processes [<xref rid="B16-pharmaceutics-11-00021" ref-type="bibr">16</xref>]. The offer of a &#x0201c;greener&#x0201d; route [<xref rid="B16-pharmaceutics-11-00021" ref-type="bibr">16</xref>] using little to no organic solvents during pharmaceutical formulation processing, and a &#x0201c;cleaner&#x0201d; product whereby the efficient removal of the residual solvent by supercritical CO<sub>2</sub>, and its microbial inactivation abilities, makes supercritical fluid technologies very favorable for pharmaceutical manufacturing industries.</p><p>From the available literature, it can be seen that the mechanism and various configurations of supercritical CO<sub>2</sub> processes has already been studied extensively, providing a well-established database for both thermodynamic (density, viscosity, solubility at different temperature, pressure conditions, etc.) [<xref rid="B113-pharmaceutics-11-00021" ref-type="bibr">113</xref>,<xref rid="B114-pharmaceutics-11-00021" ref-type="bibr">114</xref>,<xref rid="B115-pharmaceutics-11-00021" ref-type="bibr">115</xref>,<xref rid="B116-pharmaceutics-11-00021" ref-type="bibr">116</xref>] and fluid dynamic behavior (jet break-up, mass transfer, etc.) [<xref rid="B58-pharmaceutics-11-00021" ref-type="bibr">58</xref>,<xref rid="B59-pharmaceutics-11-00021" ref-type="bibr">59</xref>]. A focus on the research and development of systems in compliance with pharmaceutical manufacturing practices, with a clear evaluation of health and safety guidelines and considerations for operation, and complete with a techno-economic model of the technology, will help realize its potential for implementation and scale-up in pharmaceutical processes in the near future.</p></sec></body><back><ack><title>Acknowledgments</title><p>The authors would like to acknowledge the research support funding by Newcastle University in Singapore for the preparation and publication of this review. The support from Chi-Hwa Wang, National University of Singapore, Department of Chemical and Biomolecular Engineering on the use of their supercritical fluid facilities is deeply appreciated.</p></ack><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-pharmaceutics-11-00021"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ginty</surname><given-names>P.J.</given-names></name><name><surname>Whitaker</surname><given-names>M.J.</given-names></name><name><surname>Shakesheff</surname><given-names>K.M.</given-names></name><name><surname>Howdle</surname><given-names>S.M.</given-names></name></person-group><article-title>Drug delivery goes supercritical</article-title><source>Mater. Today</source><year>2005</year><volume>8</volume><fpage>42</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1016/S1369-7021(05)71036-1</pub-id></element-citation></ref><ref id="B2-pharmaceutics-11-00021"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuchuchua</surname><given-names>O.</given-names></name><name><surname>Nejadnik</surname><given-names>M.R.</given-names></name><name><surname>Goulooze</surname><given-names>S.C.</given-names></name><name><surname>Lje&#x00161;kovi&#x00107;</surname><given-names>N.J.</given-names></name><name><surname>Every</surname><given-names>H.A.</given-names></name><name><surname>Jiskoot</surname><given-names>W.</given-names></name></person-group><article-title>Characterization of drug delivery particles produced by supercritical carbon dioxide technologies</article-title><source>J. Supercrit. Fluids</source><year>2017</year><volume>128</volume><fpage>244</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2017.06.002</pub-id></element-citation></ref><ref id="B3-pharmaceutics-11-00021"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>O.R.</given-names></name><name><surname>Lewis</surname><given-names>A.L.</given-names></name><name><surname>Whitaker</surname><given-names>M.J.</given-names></name><name><surname>Tai</surname><given-names>H.</given-names></name><name><surname>Shakesheff</surname><given-names>K.M.</given-names></name><name><surname>Howdle</surname><given-names>S.M.</given-names></name></person-group><article-title>Applications of supercritical CO<sub>2</sub> in the fabrication of polymer systems for drug delivery and tissue engineering</article-title><source>Adv. Drug Deliv. Rev.</source><year>2008</year><volume>60</volume><fpage>373</fpage><lpage>387</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2006.12.001</pub-id><?supplied-pmid 18069079?><pub-id pub-id-type="pmid">18069079</pub-id></element-citation></ref><ref id="B4-pharmaceutics-11-00021"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fahim</surname><given-names>T.K.</given-names></name><name><surname>Zaidul</surname><given-names>I.S.M.</given-names></name><name><surname>Abu Bakar</surname><given-names>M.R.</given-names></name><name><surname>Salim</surname><given-names>U.M.</given-names></name><name><surname>Awang</surname><given-names>M.B.</given-names></name><name><surname>Sahena</surname><given-names>F.</given-names></name><name><surname>Jalal</surname><given-names>K.C.A.</given-names></name><name><surname>Sharif</surname><given-names>K.M.</given-names></name><name><surname>Sohrab</surname><given-names>M.H.</given-names></name></person-group><article-title>Particle formation and micronization using non-conventional techniques&#x02014;Review</article-title><source>Chem. Eng. Process. Process Intensif.</source><year>2014</year><volume>86</volume><fpage>47</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1016/j.cep.2014.10.009</pub-id></element-citation></ref><ref id="B5-pharmaceutics-11-00021"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasquali</surname><given-names>I.</given-names></name><name><surname>Bettini</surname><given-names>R.</given-names></name></person-group><article-title>Are pharmaceutics really going supercritical?</article-title><source>Int. J. Pharm.</source><year>2008</year><volume>364</volume><fpage>176</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2008.05.014</pub-id><?supplied-pmid 18597957?><pub-id pub-id-type="pmid">18597957</pub-id></element-citation></ref><ref id="B6-pharmaceutics-11-00021"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esfandiari</surname><given-names>N.</given-names></name></person-group><article-title>Production of micro and nano particles of pharmaceutical by supercritical carbon dioxide</article-title><source>J. Supercrit. Fluids</source><year>2015</year><volume>100</volume><fpage>129</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2014.12.028</pub-id></element-citation></ref><ref id="B7-pharmaceutics-11-00021"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cocero</surname><given-names>M.J.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>&#x000c1;.</given-names></name><name><surname>Mattea</surname><given-names>F.</given-names></name><name><surname>Varona</surname><given-names>S.</given-names></name></person-group><article-title>Encapsulation and co-precipitation processes with supercritical fluids: Fundamentals and applications</article-title><source>J. Supercrit. Fluids</source><year>2009</year><volume>47</volume><fpage>546</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2008.08.015</pub-id></element-citation></ref><ref id="B8-pharmaceutics-11-00021"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kankala</surname><given-names>R.K.</given-names></name><name><surname>Zhang</surname><given-names>Y.S.</given-names></name><name><surname>Wang</surname><given-names>S.B.</given-names></name><name><surname>Lee</surname><given-names>C.H.</given-names></name><name><surname>Chen</surname><given-names>A.Z.</given-names></name></person-group><article-title>Supercritical fluid technology: An emphasis on drug delivery and related biomedical applications</article-title><source>Adv. Healthc. Mater.</source><year>2017</year><volume>6</volume><pub-id pub-id-type="doi">10.1002/adhm.201700433</pub-id></element-citation></ref><ref id="B9-pharmaceutics-11-00021"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabernero</surname><given-names>A.</given-names></name><name><surname>Mart&#x000ed;n del Valle</surname><given-names>E.M.</given-names></name><name><surname>Gal&#x000e1;n</surname><given-names>M.A.</given-names></name></person-group><article-title>Supercritical fluids for pharmaceutical particle engineering: Methods, basic fundamentals and modelling</article-title><source>Chem. Eng. Process. Process Intensif.</source><year>2012</year><volume>60</volume><fpage>9</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.cep.2012.06.004</pub-id></element-citation></ref><ref id="B10-pharmaceutics-11-00021"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>L.Y.</given-names></name><name><surname>Wang</surname><given-names>C.H.</given-names></name><name><surname>Smith</surname><given-names>K.A.</given-names></name></person-group><article-title>Supercritical antisolvent production of biodegradable micro- and nanoparticles for controlled delivery of paclitaxel</article-title><source>J. Control. Release</source><year>2008</year><volume>125</volume><fpage>96</fpage><lpage>106</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2007.10.002</pub-id><pub-id pub-id-type="pmid">18054107</pub-id></element-citation></ref><ref id="B11-pharmaceutics-11-00021"><label>11.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>L.Y.</given-names></name><name><surname>Smith</surname><given-names>K.A.</given-names></name><name><surname>Wang</surname><given-names>C.-H.</given-names></name></person-group><article-title>Fabrication of controlled release devices for anticancer agents using supercritical antisolvent method</article-title><source>Proceedings of the AIChE Annual Meeting</source><conf-loc>Cincinnati, OH, USA</conf-loc><conf-date>30 October&#x02013;4 November 2005</conf-date></element-citation></ref><ref id="B12-pharmaceutics-11-00021"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>L.Y.</given-names></name><name><surname>Ranganath</surname><given-names>S.H.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Zheng</surname><given-names>J.L.</given-names></name><name><surname>Lee</surname><given-names>H.S.</given-names></name><name><surname>Wang</surname><given-names>C.-H.</given-names></name><name><surname>Smith</surname><given-names>K.A.</given-names></name></person-group><article-title>Paclitaxel release from micro-porous PLGA disks</article-title><source>Chem. Eng. Sci.</source><year>2009</year><volume>64</volume><fpage>4341</fpage><lpage>4349</lpage><pub-id pub-id-type="doi">10.1016/j.ces.2009.07.016</pub-id></element-citation></ref><ref id="B13-pharmaceutics-11-00021"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>L.Y.</given-names></name><name><surname>Tong</surname><given-names>H.</given-names></name><name><surname>Wang</surname><given-names>C.-H.</given-names></name></person-group><article-title>PLGA/chitosan composites from a combination of spray drying and supercritical fluid foaming techniques: New carriers for DNA delivery</article-title><source>J. Control. Release</source><year>2008</year><volume>129</volume><fpage>207</fpage><lpage>214</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2008.04.018</pub-id><?supplied-pmid 18539352?><pub-id pub-id-type="pmid">18539352</pub-id></element-citation></ref><ref id="B14-pharmaceutics-11-00021"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>X.H.</given-names></name><name><surname>Lee</surname><given-names>L.Y.</given-names></name><name><surname>Jackson</surname><given-names>J.S.H.</given-names></name><name><surname>Tong</surname><given-names>Y.W.</given-names></name><name><surname>Wang</surname><given-names>C.-H.</given-names></name></person-group><article-title>Characterization of porous poly(<sc>d</sc>,<sc>l</sc>-lactic-<italic>co</italic>-glycolic acid) sponges fabricated by supercritical CO<sub>2</sub> gas-foaming method as a scaffold for three-dimensional growth of Hep3B cells</article-title><source>Biotechnol. Bioeng.</source><year>2008</year><volume>100</volume><fpage>998</fpage><lpage>1009</lpage><pub-id pub-id-type="doi">10.1002/bit.21824</pub-id><?supplied-pmid 18551526?><pub-id pub-id-type="pmid">18551526</pub-id></element-citation></ref><ref id="B15-pharmaceutics-11-00021"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davoodi</surname><given-names>P.</given-names></name><name><surname>Lee</surname><given-names>L.Y.</given-names></name><name><surname>Xu</surname><given-names>Q.</given-names></name><name><surname>Sunil</surname><given-names>V.</given-names></name><name><surname>Sun</surname><given-names>Y.</given-names></name><name><surname>Soh</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>C.-H.</given-names></name></person-group><article-title>Drug delivery systems for programmed and on-demand release</article-title><source>Adv. Drug Deliv. Rev.</source><year>2018</year><volume>132</volume><fpage>104</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2018.07.002</pub-id><?supplied-pmid 30415656?><pub-id pub-id-type="pmid">30415656</pub-id></element-citation></ref><ref id="B16-pharmaceutics-11-00021"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Badens</surname><given-names>E.</given-names></name><name><surname>Masmoudi</surname><given-names>Y.</given-names></name><name><surname>Mouahid</surname><given-names>A.</given-names></name><name><surname>Crampon</surname><given-names>C.</given-names></name></person-group><article-title>Current situation and perspectives in drug formulation by using supercritical fluid technology</article-title><source>J. Supercrit. Fluids</source><year>2018</year><volume>134</volume><fpage>274</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2017.12.038</pub-id></element-citation></ref><ref id="B17-pharmaceutics-11-00021"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>J.</given-names></name><name><surname>Perrut</surname><given-names>M.</given-names></name></person-group><article-title>Particle design using supercritical fluids: Literature and patent survey</article-title><source>J. Supercrit. Fluids</source><year>2001</year><volume>20</volume><fpage>179</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/S0896-8446(01)00064-X</pub-id></element-citation></ref><ref id="B18-pharmaceutics-11-00021"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bahrami</surname><given-names>M.</given-names></name><name><surname>Ranjbarian</surname><given-names>S.</given-names></name></person-group><article-title>Production of micro- and nano-composite particles by supercritical carbon dioxide</article-title><source>J. Supercrit. Fluids</source><year>2007</year><volume>40</volume><fpage>263</fpage><lpage>283</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2006.05.006</pub-id></element-citation></ref><ref id="B19-pharmaceutics-11-00021"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Padrela</surname><given-names>L.</given-names></name><name><surname>Rodrigues</surname><given-names>M.A.</given-names></name><name><surname>Duarte</surname><given-names>A.</given-names></name><name><surname>Dias</surname><given-names>A.M.A.</given-names></name><name><surname>Braga</surname><given-names>M.E.M.</given-names></name><name><surname>de Sousa</surname><given-names>H.C.</given-names></name></person-group><article-title>Supercritical carbon dioxide-based technologies for the production of drug nanoparticles/nanocrystals&#x02014;A comprehensive review</article-title><source>Adv. Drug Deliv. Rev.</source><year>2018</year><volume>131</volume><fpage>22</fpage><lpage>78</lpage><pub-id pub-id-type="doi">10.1016/j.addr.2018.07.010</pub-id><pub-id pub-id-type="pmid">30026127</pub-id></element-citation></ref><ref id="B20-pharmaceutics-11-00021"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>L.Y.</given-names></name><name><surname>Lim</surname><given-names>L.K.</given-names></name><name><surname>Hua</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>C.-H.</given-names></name></person-group><article-title>Jet breakup and droplet formation in near-critical regime of carbon dioxide-dichloromethane system</article-title><source>Chem. Eng. Sci.</source><year>2008</year><volume>63</volume><fpage>3366</fpage><lpage>3378</lpage><pub-id pub-id-type="doi">10.1016/j.ces.2008.04.015</pub-id></element-citation></ref><ref id="B21-pharmaceutics-11-00021"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ong</surname><given-names>Y.X.J.</given-names></name><name><surname>Lee</surname><given-names>L.Y.</given-names></name><name><surname>Davoodi</surname><given-names>P.</given-names></name><name><surname>Wang</surname><given-names>C.H.</given-names></name></person-group><article-title>Production of drug-releasing biodegradable microporous scaffold using a two-step micro-encapsulation/supercritical foaming process</article-title><source>J. Supercrit. Fluids</source><year>2018</year><volume>133</volume><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2017.10.018</pub-id></element-citation></ref><ref id="B22-pharmaceutics-11-00021"><label>22.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>L.Y.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>C.-H.</given-names></name></person-group><article-title>Study of the supercritical drying of wet Okara</article-title><source>Proceedings of the 15th International Conference on Sustainable Energy Technologies (SET2016)</source><conf-loc>Singapore</conf-loc><conf-date>19&#x02013;22 July 2016</conf-date><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="B23-pharmaceutics-11-00021"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vemavarapu</surname><given-names>C.</given-names></name><name><surname>Mollan</surname><given-names>M.J.</given-names></name><name><surname>Lodaya</surname><given-names>M.</given-names></name><name><surname>Needham</surname><given-names>T.E.</given-names></name></person-group><article-title>Design and process aspects of laboratory scale SCF particle formation systems</article-title><source>Int. J. Pharm.</source><year>2005</year><volume>292</volume><fpage>1</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2004.07.021</pub-id><?supplied-pmid 15725549?><pub-id pub-id-type="pmid">15725549</pub-id></element-citation></ref><ref id="B24-pharmaceutics-11-00021"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jos&#x000e9;</surname><given-names>M.</given-names></name></person-group><article-title>Extraction of natural compounds using supercritical CO<sub>2</sub>: Going from the laboratory to the industrial application</article-title><source>J. Supercrit. Fluids</source><year>2015</year><volume>96</volume><fpage>180</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2014.10.001</pub-id></element-citation></ref><ref id="B25-pharmaceutics-11-00021"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharif</surname><given-names>K.M.</given-names></name><name><surname>Rahman</surname><given-names>M.M.</given-names></name><name><surname>Azmir</surname><given-names>J.</given-names></name><name><surname>Mohamed</surname><given-names>A.</given-names></name><name><surname>Jahurul</surname><given-names>M.H.A.</given-names></name><name><surname>Sahena</surname><given-names>F.</given-names></name><name><surname>Zaidul</surname><given-names>I.S.M.</given-names></name></person-group><article-title>Experimental design of supercritical fluid extraction&#x02014;A review</article-title><source>J. Food Eng.</source><year>2014</year><volume>124</volume><fpage>105</fpage><lpage>116</lpage><pub-id pub-id-type="doi">10.1016/j.jfoodeng.2013.10.003</pub-id></element-citation></ref><ref id="B26-pharmaceutics-11-00021"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Melo</surname><given-names>M.M.R.</given-names></name><name><surname>Silvestre</surname><given-names>A.J.D.</given-names></name><name><surname>Silva</surname><given-names>C.M.</given-names></name></person-group><article-title>Supercritical fluid extraction of vegetable matrices: Applications, trends and future perspectives of a convincing green technology</article-title><source>J. Supercrit. Fluids</source><year>2014</year><volume>92</volume><fpage>115</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2014.04.007</pub-id></element-citation></ref><ref id="B27-pharmaceutics-11-00021"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vergara-Mendoza</surname><given-names>M.D.S.</given-names></name><name><surname>Ortiz-Estrada</surname><given-names>C.H.</given-names></name><name><surname>Gonz&#x000e1;lez-Mart&#x000ed;nez</surname><given-names>J.</given-names></name><name><surname>Quezada-Gallo</surname><given-names>J.A.</given-names></name></person-group><article-title>Microencapsulation of coenzyme Q<sub>10</sub> in poly(ethylene glycol) and poly(lactic acid) with supercritical carbon dioxide</article-title><source>Ind. Eng. Chem. Res.</source><year>2012</year><volume>51</volume><fpage>5840</fpage><lpage>5846</lpage><pub-id pub-id-type="doi">10.1021/ie2014839</pub-id></element-citation></ref><ref id="B28-pharmaceutics-11-00021"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiou</surname><given-names>A.H.J.</given-names></name><name><surname>Cheng</surname><given-names>H.C.</given-names></name><name><surname>Wang</surname><given-names>D.P.</given-names></name></person-group><article-title>Micronization and microencapsulation of felodipine by supercritical carbon dioxide</article-title><source>J. Microencapsul.</source><year>2006</year><volume>23</volume><fpage>265</fpage><lpage>276</lpage><pub-id pub-id-type="doi">10.1080/02652040500435071</pub-id><?supplied-pmid 16801239?><pub-id pub-id-type="pmid">16801239</pub-id></element-citation></ref><ref id="B29-pharmaceutics-11-00021"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Q.</given-names></name><name><surname>Ou</surname><given-names>C.</given-names></name><name><surname>Ye</surname><given-names>S.</given-names></name><name><surname>Song</surname><given-names>X.</given-names></name><name><surname>Luo</surname><given-names>S.</given-names></name></person-group><article-title>Construction of nanoscale liposomes loaded with melatonin via supercritical fluid technology</article-title><source>J. Microencapsul.</source><year>2017</year><volume>34</volume><fpage>687</fpage><lpage>698</lpage><pub-id pub-id-type="doi">10.1080/02652048.2017.1376001</pub-id><?supplied-pmid 28866966?><pub-id pub-id-type="pmid">28866966</pub-id></element-citation></ref><ref id="B30-pharmaceutics-11-00021"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Paxton</surname><given-names>T.E.</given-names></name><name><surname>Tomasko</surname><given-names>D.L.</given-names></name></person-group><article-title>Microencapsulation of naproxen using rapid expansion of supercritical solutions</article-title><source>Biotechnol. Prog.</source><year>1996</year><volume>12</volume><fpage>650</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1021/bp9600492</pub-id></element-citation></ref><ref id="B31-pharmaceutics-11-00021"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O&#x02019;Neill</surname><given-names>M.L.</given-names></name><name><surname>Cao</surname><given-names>Q.</given-names></name><name><surname>Fang</surname><given-names>M.</given-names></name><name><surname>Johnston</surname><given-names>K.P.</given-names></name><name><surname>Wilkinson</surname><given-names>S.P.</given-names></name><name><surname>Smith</surname><given-names>C.D.</given-names></name><name><surname>Kerschner</surname><given-names>J.L.</given-names></name><name><surname>Jureller</surname><given-names>S.H.</given-names></name></person-group><article-title>Solubility of homopolymers and copolymers in carbon dioxide</article-title><source>Ind. Eng. Chem. Res.</source><year>1998</year><volume>37</volume><fpage>3067</fpage><lpage>3079</lpage><pub-id pub-id-type="doi">10.1021/ie980010x</pub-id></element-citation></ref><ref id="B32-pharmaceutics-11-00021"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mishima</surname><given-names>K.</given-names></name><name><surname>Matsuyama</surname><given-names>K.</given-names></name><name><surname>Tanabe</surname><given-names>D.</given-names></name><name><surname>Yamauchi</surname><given-names>S.</given-names></name><name><surname>Young</surname><given-names>T.J.</given-names></name><name><surname>Johnston</surname><given-names>K.P.</given-names></name></person-group><article-title>Microencapsulation of proteins by rapid expansion of supercritical solution with a nonsolvent</article-title><source>AIChE J.</source><year>2000</year><volume>46</volume><fpage>857</fpage><lpage>865</lpage><pub-id pub-id-type="doi">10.1002/aic.690460418</pub-id></element-citation></ref><ref id="B33-pharmaceutics-11-00021"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>D.J.</given-names></name><name><surname>Johnston</surname><given-names>K.P.</given-names></name><name><surname>Bodmeier</surname><given-names>R.A.</given-names></name></person-group><article-title>Polymeric materials formed by precipitation with a compressed fluid antisolvent</article-title><source>AIChE J.</source><year>1993</year><volume>39</volume><fpage>127</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1002/aic.690390113</pub-id></element-citation></ref><ref id="B34-pharmaceutics-11-00021"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>K.</given-names></name><name><surname>Mishima</surname><given-names>K.</given-names></name><name><surname>Hayashi</surname><given-names>K.I.</given-names></name><name><surname>Ishikawa</surname><given-names>H.</given-names></name><name><surname>Matsuyama</surname><given-names>H.</given-names></name><name><surname>Harada</surname><given-names>T.</given-names></name></person-group><article-title>Formation of microcapsules of medicines by the rapid expansion of a supercritical solution with a nonsolvent</article-title><source>J. Appl. Polym. Sci.</source><year>2003</year><volume>89</volume><fpage>742</fpage><lpage>752</lpage><pub-id pub-id-type="doi">10.1002/app.12201</pub-id></element-citation></ref><ref id="B35-pharmaceutics-11-00021"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Visentin</surname><given-names>A.</given-names></name><name><surname>Rodr&#x000ed;guez-Rojo</surname><given-names>S.</given-names></name><name><surname>Navarrete</surname><given-names>A.</given-names></name><name><surname>Maestri</surname><given-names>D.</given-names></name><name><surname>Cocero</surname><given-names>M.J.</given-names></name></person-group><article-title>Precipitation and encapsulation of rosemary antioxidants by supercritical antisolvent process</article-title><source>J. Food Eng.</source><year>2012</year><volume>109</volume><fpage>9</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1016/j.jfoodeng.2011.10.015</pub-id></element-citation></ref><ref id="B36-pharmaceutics-11-00021"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mezzomo</surname><given-names>N.</given-names></name><name><surname>De Paz</surname><given-names>E.</given-names></name><name><surname>Maraschin</surname><given-names>M.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>&#x000c1;.</given-names></name><name><surname>Cocero</surname><given-names>M.J.</given-names></name><name><surname>Ferreira</surname><given-names>S.R.S.</given-names></name></person-group><article-title>Supercritical anti-solvent precipitation of carotenoid fraction from pink shrimp residue: Effect of operational conditions on encapsulation efficiency</article-title><source>J. Supercrit. Fluids</source><year>2012</year><volume>66</volume><fpage>342</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2011.08.006</pub-id></element-citation></ref><ref id="B37-pharmaceutics-11-00021"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;n</surname><given-names>V.</given-names></name><name><surname>Romero-D&#x000ed;ez</surname><given-names>R.</given-names></name><name><surname>Rodr&#x000ed;guez-Rojo</surname><given-names>S.</given-names></name><name><surname>Cocero</surname><given-names>M.J.</given-names></name></person-group><article-title>Titnium dioxide nanoparticle coating in fluidized bed via supercritical anti-solvent process (SAS)</article-title><source>Chem. Eng. J.</source><year>2015</year><volume>279</volume><fpage>425</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1016/j.cej.2015.05.014</pub-id></element-citation></ref><ref id="B38-pharmaceutics-11-00021"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montes</surname><given-names>A.</given-names></name><name><surname>Kin</surname><given-names>N.</given-names></name><name><surname>Gordillo</surname><given-names>M.D.</given-names></name><name><surname>Pereyra</surname><given-names>C.</given-names></name><name><surname>De La Ossa</surname><given-names>E.J.M.</given-names></name></person-group><article-title>Polymer-naproxen precipitation by supercritical antisolvent (SAS) process</article-title><source>J. Supercrit. Fluids</source><year>2014</year><volume>89</volume><fpage>58</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2014.02.004</pub-id></element-citation></ref><ref id="B39-pharmaceutics-11-00021"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prosapio</surname><given-names>V.</given-names></name><name><surname>De Marco</surname><given-names>I.</given-names></name><name><surname>Reverchon</surname><given-names>E.</given-names></name></person-group><article-title>Supercritical antisolvent coprecipitation mechanisms</article-title><source>J. Supercrit. Fluids</source><year>2018</year><volume>138</volume><fpage>247</fpage><lpage>258</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2018.04.021</pub-id></element-citation></ref><ref id="B40-pharmaceutics-11-00021"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prosapio</surname><given-names>V.</given-names></name><name><surname>De Marco</surname><given-names>I.</given-names></name><name><surname>Scognamiglio</surname><given-names>M.</given-names></name><name><surname>Reverchon</surname><given-names>E.</given-names></name></person-group><article-title>Folic acid-PVP nanostructured composite microparticles by supercritical antisolvent precipitation</article-title><source>Chem. Eng. J.</source><year>2015</year><volume>277</volume><fpage>286</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1016/j.cej.2015.04.149</pub-id></element-citation></ref><ref id="B41-pharmaceutics-11-00021"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abuzar</surname><given-names>S.M.</given-names></name><name><surname>Hyun</surname><given-names>S.M.</given-names></name><name><surname>Kim</surname><given-names>J.H.</given-names></name><name><surname>Park</surname><given-names>H.J.</given-names></name><name><surname>Kim</surname><given-names>M.S.</given-names></name><name><surname>Park</surname><given-names>J.S.</given-names></name><name><surname>Hwang</surname><given-names>S.J.</given-names></name></person-group><article-title>Enhancing the solubility and bioavailability of poorly water-soluble drugs using supercritical antisolvent (SAS) process</article-title><source>Int. J. Pharm.</source><year>2018</year><volume>538</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2017.12.041</pub-id><pub-id pub-id-type="pmid">29278733</pub-id></element-citation></ref><ref id="B42-pharmaceutics-11-00021"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>F.R.S.</given-names></name><name><surname>Reis</surname><given-names>D.F.</given-names></name><name><surname>Boschetto</surname><given-names>D.L.</given-names></name><name><surname>Burkert</surname><given-names>J.F.M.</given-names></name><name><surname>Ferreira</surname><given-names>S.R.S.</given-names></name><name><surname>Oliveira</surname><given-names>J.V.</given-names></name><name><surname>Burkert</surname><given-names>C.A.V.</given-names></name></person-group><article-title>Encapsulation of astaxanthin from <italic>Haematococcus pluvialis</italic> in PHBV by means of SEDS technique using supercritical CO<sub>2</sub></article-title><source>Ind. Crops Prod.</source><year>2014</year><volume>54</volume><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.indcrop.2014.01.007</pub-id></element-citation></ref><ref id="B43-pharmaceutics-11-00021"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perrut</surname><given-names>M.</given-names></name></person-group><article-title>Supercritical fluid applications: Industrial developments and economic issues</article-title><source>Ind. Eng. Chem. Res.</source><year>2000</year><volume>39</volume><fpage>4531</fpage><lpage>4535</lpage><pub-id pub-id-type="doi">10.1021/ie000211c</pub-id></element-citation></ref><ref id="B44-pharmaceutics-11-00021"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y.</given-names></name><name><surname>Yu</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Zhao</surname><given-names>F.</given-names></name></person-group><article-title>Effect of process parameters on the recrystallization and size control of puerarin using the supercritical fluid antisolvent process</article-title><source>Asian J. Pharm. Sci.</source><year>2016</year><volume>11</volume><fpage>281</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1016/j.ajps.2015.12.001</pub-id></element-citation></ref><ref id="B45-pharmaceutics-11-00021"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>H.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Hu</surname><given-names>D.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>Preparation of PLA-PEG nanoparticles by the solution enhanced dispersion with enhanced mass transfer using ultrasound in supercritical CO<sub>2</sub></article-title><source>Powder Technol.</source><year>2012</year><volume>227</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/j.powtec.2012.04.050</pub-id></element-citation></ref><ref id="B46-pharmaceutics-11-00021"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kalani</surname><given-names>M.</given-names></name><name><surname>Yunus</surname><given-names>R.</given-names></name></person-group><article-title>Application of supercritical antisolvent method in drug encapsulation: A review</article-title><source>Int. J. Nanomed.</source><year>2011</year><volume>6</volume><fpage>1429</fpage><lpage>1442</lpage><pub-id pub-id-type="doi">10.2147/IJN.S19021</pub-id><?supplied-pmid 21796245?><pub-id pub-id-type="pmid">21796245</pub-id></element-citation></ref><ref id="B47-pharmaceutics-11-00021"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zabihi</surname><given-names>F.</given-names></name><name><surname>Xin</surname><given-names>N.</given-names></name><name><surname>Jia</surname><given-names>J.</given-names></name><name><surname>Chen</surname><given-names>T.</given-names></name><name><surname>Zhao</surname><given-names>Y.</given-names></name></person-group><article-title>High yield and high loading preparation of curcumin&#x02013;PLGA nanoparticles using a modified supercritical antisolvent technique</article-title><source>Ind. Eng. Chem. Res.</source><year>2014</year><volume>53</volume><fpage>6569</fpage><lpage>6574</lpage><pub-id pub-id-type="doi">10.1021/ie404215h</pub-id></element-citation></ref><ref id="B48-pharmaceutics-11-00021"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tu</surname><given-names>L.S.</given-names></name><name><surname>Dehghani</surname><given-names>F.</given-names></name><name><surname>Foster</surname><given-names>N.R.</given-names></name></person-group><article-title>Micronisation and microencapsulation of pharmaceuticals using a carbon dioxide antisolvent</article-title><source>Powder Technol.</source><year>2002</year><volume>126</volume><fpage>134</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/S0032-5910(02)00045-1</pub-id></element-citation></ref><ref id="B49-pharmaceutics-11-00021"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Elvassore</surname><given-names>N.</given-names></name><name><surname>Baggio</surname><given-names>M.</given-names></name><name><surname>Pallado</surname><given-names>P.</given-names></name><name><surname>Bertucco</surname><given-names>A.</given-names></name></person-group><article-title>Production of different morphologies of biocompatible polymeric materials by supercritical CO<sub>2</sub> antisolvent techniques</article-title><source>Biotechnol. Bioeng.</source><year>2001</year><volume>73</volume><fpage>449</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1002/bit.1079</pub-id><pub-id pub-id-type="pmid">11344449</pub-id></element-citation></ref><ref id="B50-pharmaceutics-11-00021"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engwicht</surname><given-names>A.</given-names></name><name><surname>Girreser</surname><given-names>U.</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>B.W.</given-names></name></person-group><article-title>Critical properties of lactide-<italic>co</italic>-glycolide polymers for the use in microparticle preparation by the Aerosol Solvent Extraction System</article-title><source>Int. J. Pharm.</source><year>1999</year><volume>185</volume><fpage>61</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(99)00127-1</pub-id><pub-id pub-id-type="pmid">10425366</pub-id></element-citation></ref><ref id="B51-pharmaceutics-11-00021"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karim</surname><given-names>F.T.</given-names></name><name><surname>Ghafoor</surname><given-names>K.</given-names></name><name><surname>Ferdosh</surname><given-names>S.</given-names></name><name><surname>Al-Juhaimi</surname><given-names>F.</given-names></name><name><surname>Ali</surname><given-names>E.</given-names></name><name><surname>Yunus</surname><given-names>K.B.</given-names></name><name><surname>Hamed</surname><given-names>M.H.</given-names></name><name><surname>Islam</surname><given-names>A.</given-names></name><name><surname>Asif</surname><given-names>M.</given-names></name><name><surname>Zaidul</surname><given-names>I.S.M.</given-names></name></person-group><article-title>Microencapsulation of fish oil using supercritical antisolvent process</article-title><source>J. Food Drug Anal.</source><year>2017</year><volume>25</volume><fpage>654</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1016/j.jfda.2016.11.017</pub-id><pub-id pub-id-type="pmid">28911651</pub-id></element-citation></ref><ref id="B52-pharmaceutics-11-00021"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Marco</surname><given-names>I.</given-names></name><name><surname>Rossmann</surname><given-names>M.</given-names></name><name><surname>Prosapio</surname><given-names>V.</given-names></name><name><surname>Reverchon</surname><given-names>E.</given-names></name><name><surname>Braeuer</surname><given-names>A.</given-names></name></person-group><article-title>Control of particle size, at micrometric and nanometric range, using supercritical antisolvent precipitation from solvent mixtures: Application to PVP</article-title><source>Chem. Eng. J.</source><year>2015</year><volume>273</volume><fpage>344</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1016/j.cej.2015.03.100</pub-id></element-citation></ref><ref id="B53-pharmaceutics-11-00021"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liparoti</surname><given-names>S.</given-names></name><name><surname>Adami</surname><given-names>R.</given-names></name><name><surname>Caputo</surname><given-names>G.</given-names></name><name><surname>Reverchon</surname><given-names>E.</given-names></name></person-group><article-title>Supercritical assisted atomization: Polyvinylpyrrolidone as carrier for drugs with poor solubility in water</article-title><source>J. Chem.</source><year>2013</year><volume>2013</volume><fpage>801069</fpage><pub-id pub-id-type="doi">10.1155/2013/801069</pub-id></element-citation></ref><ref id="B54-pharmaceutics-11-00021"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thote</surname><given-names>A.J.</given-names></name><name><surname>Gupta</surname><given-names>R.B.</given-names></name></person-group><article-title>Formation of nanoparticles of a hydrophilic drug using supercritical carbon dioxide and microencapsulation for sustained release</article-title><source>Nanomedicine</source><year>2005</year><volume>1</volume><fpage>85</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1016/j.nano.2004.12.001</pub-id><pub-id pub-id-type="pmid">17292062</pub-id></element-citation></ref><ref id="B55-pharmaceutics-11-00021"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C.</given-names></name><name><surname>Ng</surname><given-names>K.M.</given-names></name><name><surname>Wibowo</surname><given-names>C.</given-names></name></person-group><article-title>Producing nanoparticles using precipitation with compressed antisolvent</article-title><source>Ind. Eng. Chem. Res.</source><year>2007</year><volume>46</volume><fpage>3580</fpage><lpage>3589</lpage><pub-id pub-id-type="doi">10.1021/ie0611204</pub-id></element-citation></ref><ref id="B56-pharmaceutics-11-00021"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chattopadhyay</surname><given-names>P.</given-names></name><name><surname>Gupta</surname><given-names>R.B.</given-names></name></person-group><article-title>Production of griseofulvin nanoparticles using supercritical CO<sub>2</sub> antisolvent with enhanced mass transfer</article-title><source>Int. J. Pharm.</source><year>2001</year><volume>228</volume><fpage>19</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.1016/S0378-5173(01)00803-1</pub-id><pub-id pub-id-type="pmid">11576765</pub-id></element-citation></ref><ref id="B57-pharmaceutics-11-00021"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Debenedetti</surname><given-names>P.G.</given-names></name><name><surname>Tom</surname><given-names>J.W.</given-names></name><name><surname>Sang-Do</surname><given-names>Y.</given-names></name><name><surname>Gio-Bin</surname><given-names>L.</given-names></name></person-group><article-title>Application of supercritical fluids for the production of sustained delivery devices</article-title><source>J. Control. Release</source><year>1993</year><volume>24</volume><fpage>27</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/0168-3659(93)90166-3</pub-id></element-citation></ref><ref id="B58-pharmaceutics-11-00021"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;n</surname><given-names>A.</given-names></name><name><surname>Cocero</surname><given-names>M.J.</given-names></name></person-group><article-title>Numerical modeling of jet hydrodynamics, mass transfer, and crystallization kinetics in the supercritical antisolvent (SAS) process</article-title><source>J. Supercrit. Fluids</source><year>2004</year><volume>32</volume><fpage>203</fpage><lpage>219</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2004.02.009</pub-id></element-citation></ref><ref id="B59-pharmaceutics-11-00021"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petit-Gas</surname><given-names>T.</given-names></name><name><surname>Boutin</surname><given-names>O.</given-names></name><name><surname>Raspo</surname><given-names>I.</given-names></name><name><surname>Badens</surname><given-names>E.</given-names></name></person-group><article-title>Role of hydrodynamics in supercritical antisolvent processes</article-title><source>J. Supercrit. Fluids</source><year>2009</year><volume>51</volume><fpage>248</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2009.07.013</pub-id></element-citation></ref><ref id="B60-pharmaceutics-11-00021"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sauer</surname><given-names>D.</given-names></name><name><surname>Cerea</surname><given-names>M.</given-names></name><name><surname>Dinunzio</surname><given-names>J.</given-names></name><name><surname>McGinity</surname><given-names>J.</given-names></name></person-group><article-title>Dry powder coating of pharmaceuticals: A review</article-title><source>Int. J. Pharm.</source><year>2013</year><volume>457</volume><fpage>488</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1016/j.ijpharm.2013.02.032</pub-id><pub-id pub-id-type="pmid">23428881</pub-id></element-citation></ref><ref id="B61-pharmaceutics-11-00021"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>F.</given-names></name><name><surname>Haslam</surname><given-names>J.</given-names></name><name><surname>Rajewski</surname><given-names>R.</given-names></name><name><surname>Subramaniam</surname><given-names>B.</given-names></name></person-group><article-title>A fluidized-bed coating technology using near-critical carbon dioxide as fluidizing and drying medium</article-title><source>J. Supercrit. Fluids</source><year>2012</year><volume>66</volume><fpage>315</fpage><lpage>320</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2011.11.007</pub-id></element-citation></ref><ref id="B62-pharmaceutics-11-00021"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niu</surname><given-names>F.</given-names></name><name><surname>Subramaniam</surname><given-names>B.</given-names></name></person-group><article-title>Particle fluidization with supercritical carbon dioxide: Experiments and theory</article-title><source>Ind. Eng. Chem. Res.</source><year>2007</year><volume>46</volume><fpage>3153</fpage><lpage>3156</lpage><pub-id pub-id-type="doi">10.1021/ie0606789</pub-id></element-citation></ref><ref id="B63-pharmaceutics-11-00021"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matos</surname><given-names>R.L.</given-names></name><name><surname>Lu</surname><given-names>T.</given-names></name><name><surname>McConville</surname><given-names>C.</given-names></name><name><surname>Leeke</surname><given-names>G.</given-names></name><name><surname>Ingram</surname><given-names>A.</given-names></name></person-group><article-title>Analysis of curcumin precipitation and coating on lactose by the integrated supercritical antisolvent-fluidized bed process</article-title><source>J. Supercrit. Fluids</source><year>2018</year><volume>141</volume><fpage>143</fpage><lpage>156</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2017.12.013</pub-id></element-citation></ref><ref id="B64-pharmaceutics-11-00021"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q.</given-names></name><name><surname>Huang</surname><given-names>D.</given-names></name><name><surname>Lu</surname><given-names>T.</given-names></name><name><surname>Seville</surname><given-names>J.P.K.</given-names></name><name><surname>Xing</surname><given-names>L.</given-names></name><name><surname>Leeke</surname><given-names>G.A.</given-names></name></person-group><article-title>Supercritical fluid coating of API on excipient enhances drug release</article-title><source>Chem. Eng. J.</source><year>2017</year><volume>313</volume><fpage>317</fpage><lpage>327</lpage><pub-id pub-id-type="doi">10.1016/j.cej.2016.12.066</pub-id></element-citation></ref><ref id="B65-pharmaceutics-11-00021"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leeke</surname><given-names>G.A.</given-names></name><name><surname>Lu</surname><given-names>T.</given-names></name><name><surname>Bridson</surname><given-names>R.H.</given-names></name><name><surname>Seville</surname><given-names>J.P.K.</given-names></name></person-group><article-title>Application of nano-particle coatings to carrier particles using an integrated fluidized bed supercritical fluid precipitation process</article-title><source>J. Supercrit. Fluids</source><year>2014</year><volume>91</volume><fpage>7</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2014.03.012</pub-id></element-citation></ref><ref id="B66-pharmaceutics-11-00021"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chattopadhyay</surname><given-names>P.</given-names></name><name><surname>Huff</surname><given-names>R.</given-names></name><name><surname>Shekunov</surname><given-names>B.Y.</given-names></name></person-group><article-title>Drug encapsulation using supercritical fluid extraction of emulsions</article-title><source>J. Pharm. Sci.</source><year>2006</year><volume>95</volume><fpage>667</fpage><lpage>679</lpage><pub-id pub-id-type="doi">10.1002/jps.20555</pub-id><?supplied-pmid 16447174?><pub-id pub-id-type="pmid">16447174</pub-id></element-citation></ref><ref id="B67-pharmaceutics-11-00021"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giufrida</surname><given-names>W.M.</given-names></name><name><surname>Cabral</surname><given-names>V.F.</given-names></name><name><surname>Cardoso-Filho</surname><given-names>L.</given-names></name><name><surname>dos Santos Conti</surname><given-names>D.</given-names></name><name><surname>de Campos</surname><given-names>V.E.B.</given-names></name><name><surname>da Rocha</surname><given-names>S.R.P.</given-names></name></person-group><article-title>Medroxyprogesterone-encapsulated poly(3-hydroxybutirate-<italic>co</italic>-3-hydroxyvalerate) nanoparticles using supercritical fluid extraction of emulsions</article-title><source>J. Supercrit. Fluids</source><year>2016</year><volume>118</volume><fpage>79</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2016.07.026</pub-id></element-citation></ref><ref id="B68-pharmaceutics-11-00021"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kluge</surname><given-names>J.</given-names></name><name><surname>Fusaro</surname><given-names>F.</given-names></name><name><surname>Mazzotti</surname><given-names>M.</given-names></name><name><surname>Muhrer</surname><given-names>G.</given-names></name></person-group><article-title>Production of PLGA micro- and nanocomposites by supercritical fluid extraction of emulsions: II. Encapsulation of Ketoprofen</article-title><source>J. Supercrit. Fluids</source><year>2009</year><volume>50</volume><fpage>336</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2009.05.002</pub-id></element-citation></ref><ref id="B69-pharmaceutics-11-00021"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kluge</surname><given-names>J.</given-names></name><name><surname>Fusaro</surname><given-names>F.</given-names></name><name><surname>Casas</surname><given-names>N.</given-names></name><name><surname>Mazzotti</surname><given-names>M.</given-names></name><name><surname>Muhrer</surname><given-names>G.</given-names></name></person-group><article-title>Production of PLGA micro- and nanocomposites by supercritical fluid extraction of emulsions: I. Encapsulation of lysozyme</article-title><source>J. Supercrit. Fluids</source><year>2009</year><volume>50</volume><fpage>327</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2009.05.010</pub-id></element-citation></ref><ref id="B70-pharmaceutics-11-00021"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto</surname><given-names>C.</given-names></name><name><surname>Calvo</surname><given-names>L.</given-names></name></person-group><article-title>The encapsulation of low viscosity omega-3 rich fish oil in polycaprolactone by supercritical fluid extraction of emulsions</article-title><source>J. Supercrit. Fluids</source><year>2017</year><volume>128</volume><fpage>227</fpage><lpage>234</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2017.06.003</pub-id></element-citation></ref><ref id="B71-pharmaceutics-11-00021"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto</surname><given-names>C.</given-names></name><name><surname>Calvo</surname><given-names>L.</given-names></name></person-group><article-title>Supercritical fluid extraction of emulsions to nanoencapsulate vitamin E in polycaprolactone</article-title><source>J. Supercrit. Fluids</source><year>2017</year><volume>119</volume><fpage>274</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2016.10.004</pub-id></element-citation></ref><ref id="B72-pharmaceutics-11-00021"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prieto</surname><given-names>C.</given-names></name><name><surname>Calvo</surname><given-names>L.</given-names></name><name><surname>Duarte</surname><given-names>C.M.M.</given-names></name></person-group><article-title>Continuous supercritical fluid extraction of emulsions to produce nanocapsules of vitamin E in polycaprolactone</article-title><source>J. Supercrit. Fluids</source><year>2017</year><volume>124</volume><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2017.01.014</pub-id></element-citation></ref><ref id="B73-pharmaceutics-11-00021"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabirzyanov</surname><given-names>A.N.</given-names></name><name><surname>Il&#x02019;in</surname><given-names>A.P.</given-names></name><name><surname>Akhunov</surname><given-names>A.R.</given-names></name><name><surname>Gumerov</surname><given-names>F.M.</given-names></name></person-group><article-title>Solubility of water in supercritical carbon dioxide</article-title><source>High Temp.</source><year>2002</year><volume>40</volume><fpage>203</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.1023/A:1015294905132</pub-id></element-citation></ref><ref id="B74-pharmaceutics-11-00021"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>B.</given-names></name><name><surname>Choi</surname><given-names>Y.</given-names></name><name><surname>Lee</surname><given-names>W.</given-names></name></person-group><article-title>Drying characteristics of apple slabs after pretreatment with supercritical CO<sub>2</sub></article-title><source>Prev. Nutr. Food Sci.</source><year>2011</year><volume>16</volume><fpage>261</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.3746/jfn.2011.16.3.261</pub-id></element-citation></ref><ref id="B75-pharmaceutics-11-00021"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>Z.K.</given-names></name><name><surname>Fryer</surname><given-names>P.J.</given-names></name><name><surname>Norton</surname><given-names>I.T.</given-names></name><name><surname>Bakalis</surname><given-names>S.</given-names></name><name><surname>Bridson</surname><given-names>R.H.</given-names></name></person-group><article-title>Drying of foods using supercritical carbon dioxide&#x02014;Investigations with carrot</article-title><source>Innov. Food Sci. Emerg. Technol.</source><year>2008</year><volume>9</volume><fpage>280</fpage><lpage>289</lpage><pub-id pub-id-type="doi">10.1016/j.ifset.2007.07.003</pub-id></element-citation></ref><ref id="B76-pharmaceutics-11-00021"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Almeida-rivera</surname><given-names>C.</given-names></name><name><surname>Khalloufi</surname><given-names>S.</given-names></name><name><surname>Jansen</surname><given-names>J.</given-names></name><name><surname>Bongers</surname><given-names>P.</given-names></name></person-group><article-title>Mathematical description of mass transfer in supercritical-carbon-dioxide-drying processes</article-title><source>Comput. Aided Chem. Eng.</source><year>2011</year><volume>29</volume><fpage>36</fpage><lpage>40</lpage></element-citation></ref><ref id="B77-pharmaceutics-11-00021"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalloufi</surname><given-names>S.</given-names></name><name><surname>Almeida-rivera</surname><given-names>C.</given-names></name><name><surname>Bongers</surname><given-names>P.</given-names></name></person-group><article-title>Supercritical-CO<sub>2</sub> drying of foodstuffs in packed beds: Experimental validation of a mathematical model and sensitive analysis</article-title><source>J. Food Eng.</source><year>2010</year><volume>96</volume><fpage>141</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1016/j.jfoodeng.2009.07.005</pub-id></element-citation></ref><ref id="B78-pharmaceutics-11-00021"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x0015e;ahin</surname><given-names>&#x00130;.</given-names></name><name><surname>&#x000d6;zbak&#x00131;r</surname><given-names>Y.</given-names></name><name><surname>&#x00130;n&#x000f6;n&#x000fc;</surname><given-names>Z.</given-names></name><name><surname>Ulker</surname><given-names>Z.</given-names></name><name><surname>Erkey</surname><given-names>C.</given-names></name></person-group><article-title>Kinetics of Supercritical Drying of Gels</article-title><source>Gels</source><year>2018</year><volume>4</volume><elocation-id>3</elocation-id><pub-id pub-id-type="doi">10.3390/gels4010003</pub-id></element-citation></ref><ref id="B79-pharmaceutics-11-00021"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name></person-group><article-title>Preparation of silica aerogel from rice hull ash by supercritical carbon dioxide drying</article-title><source>J. Supercrit. Fluids</source><year>2005</year><volume>35</volume><fpage>91</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2004.12.003</pub-id></element-citation></ref><ref id="B80-pharmaceutics-11-00021"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>&#x000d6;zbak&#x00131;r</surname><given-names>Y.</given-names></name><name><surname>Erkey</surname><given-names>C.</given-names></name></person-group><article-title>Experimental and theoretical investigation of supercritical drying of silica alcogels</article-title><source>J. Supercrit. Fluids</source><year>2015</year><volume>98</volume><fpage>153</fpage><lpage>166</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2014.12.001</pub-id></element-citation></ref><ref id="B81-pharmaceutics-11-00021"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sanz-moral</surname><given-names>L.M.</given-names></name><name><surname>Rueda</surname><given-names>M.</given-names></name><name><surname>Mato</surname><given-names>R.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>&#x000c1;.</given-names></name></person-group><article-title>View cell investigation of silica aerogels during supercritical drying: Analysis of size variation and mass transfer mechanisms</article-title><source>J. Supercrit. Fluids</source><year>2014</year><volume>92</volume><fpage>24</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2014.05.004</pub-id></element-citation></ref><ref id="B82-pharmaceutics-11-00021"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Griffin</surname><given-names>J.S.</given-names></name><name><surname>Mills</surname><given-names>D.H.</given-names></name><name><surname>Cleary</surname><given-names>M.</given-names></name><name><surname>Nelson</surname><given-names>R.</given-names></name><name><surname>Manno</surname><given-names>V.P.</given-names></name><name><surname>Hodes</surname><given-names>M.</given-names></name></person-group><article-title>Fluids continuous extraction rate measurements during supercritical CO<sub>2</sub> drying of silica alcogel</article-title><source>J. Supercrit. Fluids</source><year>2014</year><volume>94</volume><fpage>38</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2014.05.020</pub-id></element-citation></ref><ref id="B83-pharmaceutics-11-00021"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Paz</surname><given-names>E.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>&#x000c1;.</given-names></name><name><surname>Every</surname><given-names>H.</given-names></name><name><surname>Cocero</surname><given-names>M.J.</given-names></name></person-group><article-title>Production of water-soluble quercetin formulations by antisolvent precipitation and supercritical drying</article-title><source>J. Supercrit. Fluids</source><year>2015</year><volume>104</volume><fpage>281</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2015.07.006</pub-id></element-citation></ref><ref id="B84-pharmaceutics-11-00021"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hee</surname><given-names>Y.Y.</given-names></name><name><surname>Tan</surname><given-names>C.P.</given-names></name><name><surname>Rahman</surname><given-names>R.A.</given-names></name><name><surname>Noranizan</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>R.L.</given-names></name><name><surname>Chong</surname><given-names>G.H.</given-names></name></person-group><article-title>Production of virgin coconut oil microcapsules from oil-in-water emulsion with supercritical carbon dioxide spray drying</article-title><source>J. Supercrit. Fluids</source><year>2017</year><volume>130</volume><fpage>118</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2017.07.037</pub-id></element-citation></ref><ref id="B85-pharmaceutics-11-00021"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W.J.</given-names></name><name><surname>Tan</surname><given-names>C.P.</given-names></name><name><surname>Sulaiman</surname><given-names>R.</given-names></name><name><surname>Smith</surname><given-names>R.L.</given-names></name><name><surname>Chong</surname><given-names>G.H.</given-names></name></person-group><article-title>Microencapsulation of red palm oil as an oil-in-water emulsion with supercritical carbon dioxide solution-enhanced dispersion</article-title><source>J. Food Eng.</source><year>2018</year><volume>222</volume><fpage>100</fpage><lpage>109</lpage><pub-id pub-id-type="doi">10.1016/j.jfoodeng.2017.11.011</pub-id></element-citation></ref><ref id="B86-pharmaceutics-11-00021"><label>86.</label><element-citation publication-type="patent"><person-group person-group-type="author"><name><surname>Poortinga</surname><given-names>A.T.</given-names></name><name><surname>Trambitas</surname><given-names>D.O.</given-names></name><name><surname>Hofland</surname><given-names>G.W.</given-names></name></person-group><article-title>The Microencapsulate and Process for the Manufacture Thereof 2010</article-title><source>European Patent</source><patent>No. EP 2 315 584 B1</patent><comment>WO Patent Application 2010/014011 A1</comment><day>4</day><month>2</month><year>2010</year></element-citation></ref><ref id="B87-pharmaceutics-11-00021"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nuchuchua</surname><given-names>O.</given-names></name><name><surname>Every</surname><given-names>H.A.</given-names></name><name><surname>Hofland</surname><given-names>G.W.</given-names></name><name><surname>Jiskoot</surname><given-names>W.</given-names></name></person-group><article-title>Scalable organic solvent free supercritical fluid spray drying process for producing dry protein formulations</article-title><source>Eur. J. Pharm. Biopharm.</source><year>2014</year><volume>88</volume><fpage>919</fpage><lpage>930</lpage><pub-id pub-id-type="doi">10.1016/j.ejpb.2014.09.004</pub-id><?supplied-pmid 25262979?><pub-id pub-id-type="pmid">25262979</pub-id></element-citation></ref><ref id="B88-pharmaceutics-11-00021"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varona</surname><given-names>S.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>&#x000c1;.</given-names></name><name><surname>Cocero</surname><given-names>M.J.</given-names></name><name><surname>Duarte</surname><given-names>C.M.M.</given-names></name></person-group><article-title>Encapsulation of lavandin essential oil in poly-(&#x003b5;-caprolactones) by PGSS process</article-title><source>Chem. Eng. Technol.</source><year>2013</year><volume>36</volume><fpage>1187</fpage><lpage>1192</lpage><pub-id pub-id-type="doi">10.1002/ceat.201200592</pub-id></element-citation></ref><ref id="B89-pharmaceutics-11-00021"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lubary</surname><given-names>M.</given-names></name><name><surname>De Loos</surname><given-names>T.W.</given-names></name><name><surname>Ter Horst</surname><given-names>J.H.</given-names></name><name><surname>Hofland</surname><given-names>G.W.</given-names></name></person-group><article-title>Production of microparticles from milk fat products using the Supercritical Melt Micronization (ScMM) process</article-title><source>J. Supercrit. Fluids</source><year>2011</year><volume>55</volume><fpage>1079</fpage><lpage>1088</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2010.10.010</pub-id></element-citation></ref><ref id="B90-pharmaceutics-11-00021"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;n&#x000fc;kl&#x000fc;</surname><given-names>P.</given-names></name><name><surname>Jansens</surname><given-names>P.J.</given-names></name></person-group><article-title>Particle formation of an edible fat (rapeseed 70) using the supercritical melt micronization (ScMM) process</article-title><source>J. Supercrit. Fluids</source><year>2007</year><volume>40</volume><fpage>433</fpage><lpage>442</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2006.07.015</pub-id></element-citation></ref><ref id="B91-pharmaceutics-11-00021"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Letourneau</surname><given-names>J.J.</given-names></name><name><surname>Vigneau</surname><given-names>S.</given-names></name><name><surname>Gonus</surname><given-names>P.</given-names></name><name><surname>Fages</surname><given-names>J.</given-names></name></person-group><article-title>Micronized cocoa butter particles produced by a supercritical process</article-title><source>Chem. Eng. Process. Process Intensif.</source><year>2005</year><volume>44</volume><fpage>201</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1016/j.cep.2004.03.013</pub-id></element-citation></ref><ref id="B92-pharmaceutics-11-00021"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ciftci</surname><given-names>O.N.</given-names></name><name><surname>Temelli</surname><given-names>F.</given-names></name></person-group><article-title>Formation of solid lipid microparticles from fully hydrogenated canola oil using supercritical carbon dioxide</article-title><source>J. Food Eng.</source><year>2016</year><volume>178</volume><fpage>137</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1016/j.jfoodeng.2016.01.014</pub-id></element-citation></ref><ref id="B93-pharmaceutics-11-00021"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varona</surname><given-names>S.</given-names></name><name><surname>Kareth</surname><given-names>S.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>&#x000c1;.</given-names></name><name><surname>Cocero</surname><given-names>M.J.</given-names></name></person-group><article-title>Formulation of lavandin essential oil with biopolymers by PGSS for application as biocide in ecological agriculture</article-title><source>J. Supercrit. Fluids</source><year>2010</year><volume>54</volume><fpage>369</fpage><lpage>377</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2010.05.019</pub-id></element-citation></ref><ref id="B94-pharmaceutics-11-00021"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varona</surname><given-names>S.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>&#x000c1;.</given-names></name><name><surname>Cocero</surname><given-names>M.J.</given-names></name></person-group><article-title>Liposomal incorporation of lavandin essential oil by a thin-film hydration method and by particles from gas-saturated solutions</article-title><source>Ind. Eng. Chem. Res.</source><year>2011</year><volume>50</volume><fpage>2088</fpage><lpage>2097</lpage><pub-id pub-id-type="doi">10.1021/ie102016r</pub-id></element-citation></ref><ref id="B95-pharmaceutics-11-00021"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pemsel</surname><given-names>M.</given-names></name><name><surname>Schwab</surname><given-names>S.</given-names></name><name><surname>Scheurer</surname><given-names>A.</given-names></name><name><surname>Freitag</surname><given-names>D.</given-names></name><name><surname>Schatz</surname><given-names>R.</given-names></name><name><surname>Schl&#x000fc;cker</surname><given-names>E.</given-names></name></person-group><article-title>Advanced PGSS process for the encapsulation of the biopesticide Cydia pomonella granulovirus</article-title><source>J. Supercrit. Fluids</source><year>2010</year><volume>53</volume><fpage>174</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2009.12.006</pub-id></element-citation></ref><ref id="B96-pharmaceutics-11-00021"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Paz</surname><given-names>E.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>&#x000c1;.</given-names></name><name><surname>Cocero</surname><given-names>M.J.</given-names></name></person-group><article-title>Formulation of &#x003b2;-carotene with soybean lecithin by PGSS (Particles from Gas Saturated Solutions)-drying</article-title><source>J. Supercrit. Fluids</source><year>2012</year><volume>72</volume><fpage>125</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2012.08.007</pub-id></element-citation></ref><ref id="B97-pharmaceutics-11-00021"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Paz</surname><given-names>E.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>&#x000c1;.</given-names></name><name><surname>Duarte</surname><given-names>C.M.M.</given-names></name><name><surname>Cocero</surname><given-names>M.J.</given-names></name></person-group><article-title>Formulation of &#x003b2;-carotene with poly-(&#x003b5;-caprolactones) by PGSS process</article-title><source>Powder Technol.</source><year>2012</year><volume>217</volume><fpage>77</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1016/j.powtec.2011.10.011</pub-id></element-citation></ref><ref id="B98-pharmaceutics-11-00021"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Getachew</surname><given-names>A.T.</given-names></name><name><surname>Chun</surname><given-names>B.S.</given-names></name></person-group><article-title>Optimization of coffee oil flavor encapsulation using response surface methodology</article-title><source>LWT Food Sci. Technol.</source><year>2016</year><volume>70</volume><fpage>126</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1016/j.lwt.2016.02.025</pub-id></element-citation></ref><ref id="B99-pharmaceutics-11-00021"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Machado</surname><given-names>L.C.</given-names></name><name><surname>Pelegati</surname><given-names>V.B.</given-names></name><name><surname>Oliveira</surname><given-names>A.L.</given-names></name></person-group><article-title>Study of simple microparticles formation of limonene in modified starch using PGSS&#x02014;Particles from gas-saturated suspensions</article-title><source>J. Supercrit. Fluids</source><year>2016</year><volume>107</volume><fpage>260</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2015.09.023</pub-id></element-citation></ref><ref id="B100-pharmaceutics-11-00021"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haq</surname><given-names>M.</given-names></name><name><surname>Chun</surname><given-names>B.S.</given-names></name></person-group><article-title>Microencapsulation of omega-3 polyunsaturated fatty acids and astaxanthin-rich salmon oil using particles from gas saturated solutions (PGSS) process</article-title><source>LWT</source><year>2018</year><volume>92</volume><fpage>523</fpage><lpage>530</lpage><pub-id pub-id-type="doi">10.1016/j.lwt.2018.03.009</pub-id></element-citation></ref><ref id="B101-pharmaceutics-11-00021"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>L&#x000e9;vai</surname><given-names>G.</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>&#x000c1;.</given-names></name><name><surname>Moro</surname><given-names>A.</given-names></name><name><surname>Matias</surname><given-names>A.A.</given-names></name><name><surname>Gon&#x000e7;alves</surname><given-names>V.S.S.</given-names></name><name><surname>Bronze</surname><given-names>M.R.</given-names></name><name><surname>Duarte</surname><given-names>C.M.M.</given-names></name><name><surname>Rodr&#x000ed;guez-Rojo</surname><given-names>S.</given-names></name><name><surname>Cocero</surname><given-names>M.J.</given-names></name></person-group><article-title>Production of encapsulated quercetin particles using supercritical fluid technologies</article-title><source>Powder Technol.</source><year>2017</year><volume>317</volume><fpage>142</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1016/j.powtec.2017.04.041</pub-id></element-citation></ref><ref id="B102-pharmaceutics-11-00021"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabezas</surname><given-names>L.I.</given-names></name><name><surname>Gracia</surname><given-names>I.</given-names></name><name><surname>Garc&#x000ed;a</surname><given-names>M.T.</given-names></name><name><surname>De Lucas</surname><given-names>A.</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>J.F.</given-names></name></person-group><article-title>Production of biodegradable porous scaffolds impregnated with 5-fluorouracil in supercritical CO<sub>2</sub></article-title><source>J. Supercrit. Fluids</source><year>2013</year><volume>80</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2013.03.030</pub-id></element-citation></ref><ref id="B103-pharmaceutics-11-00021"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cabezas</surname><given-names>L.I.</given-names></name><name><surname>Fern&#x000e1;ndez</surname><given-names>V.</given-names></name><name><surname>Mazarro</surname><given-names>R.</given-names></name><name><surname>Gracia</surname><given-names>I.</given-names></name><name><surname>De Lucas</surname><given-names>A.</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>J.F.</given-names></name></person-group><article-title>Production of biodegradable porous scaffolds impregnated with indomethacin in supercritical CO<sub>2</sub></article-title><source>J. Supercrit. Fluids</source><year>2012</year><volume>63</volume><fpage>155</fpage><lpage>160</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2011.12.002</pub-id></element-citation></ref><ref id="B104-pharmaceutics-11-00021"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Champeau</surname><given-names>M.</given-names></name><name><surname>Thomassin</surname><given-names>J.M.</given-names></name><name><surname>Tassaing</surname><given-names>T.</given-names></name><name><surname>J&#x000e9;r&#x000f4;me</surname><given-names>C.</given-names></name></person-group><article-title>Drug loading of polymer implants by supercritical CO<sub>2</sub> assisted impregnation: A review</article-title><source>J. Control. Release</source><year>2015</year><volume>209</volume><fpage>248</fpage><lpage>259</lpage><pub-id pub-id-type="doi">10.1016/j.jconrel.2015.05.002</pub-id><?supplied-pmid 25953410?><pub-id pub-id-type="pmid">25953410</pub-id></element-citation></ref><ref id="B105-pharmaceutics-11-00021"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velasco</surname><given-names>D.</given-names></name><name><surname>Benito</surname><given-names>L.</given-names></name><name><surname>Fern&#x000e1;ndez-Guti&#x000e9;rrez</surname><given-names>M.</given-names></name><name><surname>San Rom&#x000e1;n</surname><given-names>J.</given-names></name><name><surname>Elvira</surname><given-names>C.</given-names></name></person-group><article-title>Preparation in supercritical CO<sub>2</sub> of porous poly(methyl methacrylate)-poly(<sc>l</sc>-lactic acid) (PMMA-PLA) scaffolds incorporating ibuprofen</article-title><source>J. Supercrit. Fluids</source><year>2010</year><volume>54</volume><fpage>335</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2010.05.012</pub-id></element-citation></ref><ref id="B106-pharmaceutics-11-00021"><label>106.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>L.Y.</given-names></name><name><surname>Ong</surname><given-names>B.</given-names></name><name><surname>Xie</surname><given-names>J.</given-names></name><name><surname>Smith</surname><given-names>K.A.</given-names></name><name><surname>Wang</surname><given-names>C.-H.</given-names></name></person-group><article-title>Controlled delivery of paclitaxel from micro-porous foams for the postsurgical treatment of glioma blastoma multiforme</article-title><source>Proceedings of the AIChE Annual Meeting</source><conf-loc>San Francisco, CA, USA</conf-loc><conf-date>12&#x02013;17 November 2006</conf-date></element-citation></ref><ref id="B107-pharmaceutics-11-00021"><label>107.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Kfoury</surname><given-names>M.</given-names></name><name><surname>H&#x00103;d&#x00103;rug&#x00103;</surname><given-names>N.G.</given-names></name><name><surname>H&#x00103;d&#x00103;rug&#x00103;</surname><given-names>D.I.</given-names></name><name><surname>Fourmentin</surname><given-names>S.</given-names></name></person-group><article-title>4&#x02014;Cyclodextrins as encapsulation material for flavors and aroma</article-title><source>Encapsulations</source><person-group person-group-type="editor"><name><surname>Grumezescu</surname><given-names>A.M.</given-names></name></person-group><comment>Nanotechnology in the Agri-Food Industry</comment><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2016</year><fpage>127</fpage><lpage>192</lpage><isbn>978-0-12-804307-3</isbn></element-citation></ref><ref id="B108-pharmaceutics-11-00021"><label>108.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Fenyvesi</surname><given-names>E.</given-names></name><name><surname>Szente</surname><given-names>L.</given-names></name></person-group><article-title>18&#x02014;Nanoencapsulation of flavors and aromas by cyclodextrins</article-title><source>Encapsulations</source><person-group person-group-type="editor"><name><surname>Grumezescu</surname><given-names>A.M.</given-names></name></person-group><comment>Nanotechnology in the Agri-Food Industry</comment><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2016</year><fpage>769</fpage><lpage>792</lpage><isbn>978-0-12-804307-3</isbn></element-citation></ref><ref id="B109-pharmaceutics-11-00021"><label>109.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Osorio-Tob&#x000f3;n</surname><given-names>J.F.</given-names></name><name><surname>Silva</surname><given-names>E.K.</given-names></name><name><surname>Meireles</surname><given-names>M.A.A.</given-names></name></person-group><article-title>3&#x02014;Nanoencapsulation of flavors and aromas by emerging technologies</article-title><source>Encapsulations</source><person-group person-group-type="editor"><name><surname>Grumezescu</surname><given-names>A.M.</given-names></name></person-group><comment>Nanotechnology in the Agri-Food Industry</comment><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2016</year><fpage>89</fpage><lpage>126</lpage><isbn>978-0-12-804307-3</isbn></element-citation></ref><ref id="B110-pharmaceutics-11-00021"><label>110.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Trifkovi&#x00107;</surname><given-names>K.</given-names></name><name><surname>&#x00110;or&#x00111;evi&#x00107;</surname><given-names>V.</given-names></name><name><surname>Balan&#x0010d;</surname><given-names>B.</given-names></name><name><surname>Kalu&#x00161;evi&#x00107;</surname><given-names>A.</given-names></name><name><surname>Levi&#x00107;</surname><given-names>S.</given-names></name><name><surname>Bugarski</surname><given-names>B.</given-names></name><name><surname>Nedovi&#x00107;</surname><given-names>V.</given-names></name></person-group><article-title>9&#x02014;Novel approaches in nanoencapsulation of aromas and flavors</article-title><source>Encapsulations</source><person-group person-group-type="editor"><name><surname>Grumezescu</surname><given-names>A.M.</given-names></name></person-group><comment>Nanotechnology in the Agri-Food Industry</comment><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2016</year><fpage>363</fpage><lpage>419</lpage><isbn>978-0-12-804307-3</isbn></element-citation></ref><ref id="B111-pharmaceutics-11-00021"><label>111.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zarzycki</surname><given-names>P.K.</given-names></name><name><surname>ena Fenert</surname><given-names>B.</given-names></name><name><surname>G&#x00142;&#x000f3;d</surname><given-names>B.K.</given-names></name></person-group><article-title>17&#x02014;Cyclodextrins-based nanocomplexes for encapsulation of bioactive compounds in food, cosmetics, and pharmaceutical products: Principles of supramolecular complexes formation, their influence on the antioxidative properties of target chemicals, and rec</article-title><source>Encapsulations</source><person-group person-group-type="editor"><name><surname>Grumezescu</surname><given-names>A.M.</given-names></name></person-group><comment>Nanotechnology in the Agri-Food Industry</comment><publisher-name>Academic Press</publisher-name><publisher-loc>Cambridge, MA, USA</publisher-loc><year>2016</year><fpage>717</fpage><lpage>767</lpage><isbn>978-0-12-804307-3</isbn></element-citation></ref><ref id="B112-pharmaceutics-11-00021"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adeoye</surname><given-names>O.</given-names></name><name><surname>Costa</surname><given-names>C.</given-names></name><name><surname>Casimiro</surname><given-names>T.</given-names></name><name><surname>Aguiar-Ricardo</surname><given-names>A.</given-names></name><name><surname>Cabral-Marques</surname><given-names>H.</given-names></name></person-group><article-title>Preparation of ibuprofen/hydroxypropyl-&#x003b3;-cyclodextrin inclusion complexes using supercritical CO<sub>2</sub>-assisted spray drying</article-title><source>J. Supercrit. Fluids</source><year>2018</year><volume>133</volume><fpage>479</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2017.11.009</pub-id></element-citation></ref><ref id="B113-pharmaceutics-11-00021"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000fc;n&#x000fc;kl&#x000fc;</surname><given-names>P.</given-names></name><name><surname>Wubbolts</surname><given-names>F.</given-names></name><name><surname>De Loos</surname><given-names>T.W.</given-names></name><name><surname>Jansens</surname><given-names>P.J.</given-names></name></person-group><article-title>The phase behavior of systems of supercritical CO<sub>2</sub> or propane with edible fats and a wax</article-title><source>J. Supercrit. Fluids</source><year>2006</year><volume>39</volume><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2006.01.011</pub-id></element-citation></ref><ref id="B114-pharmaceutics-11-00021"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonie</surname><given-names>P.</given-names></name><name><surname>Pereira</surname><given-names>C.G.</given-names></name></person-group><article-title>Solubility of functional compounds in supercritical CO<sub>2</sub>: Data evaluation and modelling</article-title><source>J. Food Eng.</source><year>2019</year><volume>245</volume><fpage>131</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.jfoodeng.2018.10.012</pub-id></element-citation></ref><ref id="B115-pharmaceutics-11-00021"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aminian</surname><given-names>A.</given-names></name></person-group><article-title>Estimating the solubility of different solutes in supercritical CO<sub>2</sub> covering a wide range of operating conditions by using neural network models</article-title><source>J. Supercrit. Fluids</source><year>2017</year><volume>125</volume><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.1016/j.supflu.2017.02.007</pub-id></element-citation></ref><ref id="B116-pharmaceutics-11-00021"><label>116.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>R.S.J.</given-names></name></person-group><source>Solubility in Supercritical Carbon Dioxide</source><edition>1st ed.</edition><publisher-name>CRC Press</publisher-name><publisher-loc>Boca Raton, FL, USA</publisher-loc><year>2007</year><isbn>9781420005998</isbn></element-citation></ref></ref-list></back><floats-group><fig id="pharmaceutics-11-00021-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Phase diagram of carbon dioxide (not to scale) and its properties at supercritical conditions.</p></caption><graphic xlink:href="pharmaceutics-11-00021-g001"/></fig><fig id="pharmaceutics-11-00021-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Schematic representation of the rapid expansion of supercritical solution (RESS) process.</p></caption><graphic xlink:href="pharmaceutics-11-00021-g002"/></fig><fig id="pharmaceutics-11-00021-f003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Schematic representation of supercritical antisolvent (SAS).</p></caption><graphic xlink:href="pharmaceutics-11-00021-g003"/></fig><fig id="pharmaceutics-11-00021-f004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Schematic representation of supercritical fluid extraction of emulsions (SFEE).</p></caption><graphic xlink:href="pharmaceutics-11-00021-g004"/></fig><fig id="pharmaceutics-11-00021-f005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Schematic representation of supercritical spray drying.</p></caption><graphic xlink:href="pharmaceutics-11-00021-g005"/></fig><fig id="pharmaceutics-11-00021-f006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>Schematic representation of particles from gas-saturated solutions (PGSS).</p></caption><graphic xlink:href="pharmaceutics-11-00021-g006"/></fig><fig id="pharmaceutics-11-00021-f007" orientation="portrait" position="float"><label>Figure 7</label><caption><p>Schematic representation of two-step drug encapsulation and supercritical CO<sub>2</sub> foaming.</p></caption><graphic xlink:href="pharmaceutics-11-00021-g007"/></fig><table-wrap id="pharmaceutics-11-00021-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-11-00021-t001_Table 1</object-id><label>Table 1</label><caption><p>Examples of bioproducts encapsulated using the RESS process.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Ingredient</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coating Material</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Particle Size and Morphology</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coenzyme Q<sub>10</sub></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poly(ethylene glycol) (PEG)<break/>Polylactic acid (PLA)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;10 &#x000b5;m<break/>PEG: Uniform and small spheres<break/>PLA: Spherical agglomerated microparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B27-pharmaceutics-11-00021" ref-type="bibr">27</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Felodipine</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG4000</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2&#x02013;6 &#x000b5;m<break/>Gel-like irregular mass</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B28-pharmaceutics-11-00021" ref-type="bibr">28</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Melatonin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Liposomes</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">66 nm<break/>Round or oval microspheres with uniform distribution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B29-pharmaceutics-11-00021" ref-type="bibr">29</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Naproxen</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10&#x02013;90 &#x000b5;m<break/>Microspheres with agglomerates</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B30-pharmaceutics-11-00021" ref-type="bibr">30</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceutics-11-00021-t002" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-11-00021-t002_Table 2</object-id><label>Table 2</label><caption><p>Examples of microencapsulation applications by the rapid expansion of supercritical solutions with a non-solvent (RESS-N).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Ingredient</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coating Material</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Co-Solvent</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Proteins (lysozyme and lipase)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG4000, PEG6000, PEG20000, poly(methyl methacrylate) (PMMA), PLA, polyglycolide-<italic>co</italic>-lactide (PGLA), and PEG- poly(propylene glycol) (PPG)-PEG triblock copolymer</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethanol/methanol/propanol/acetone/toluene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B32-pharmaceutics-11-00021" ref-type="bibr">32</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">P-acetamidophenol, acetylsalicylic acid, 1,3-dimethylxanthine, flavone, and 3-hydroxyflavone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG4000, PEG6000, PEG20000, PLA, PMMA, ethyl cellulose, and PEG-PPG-PEG triblock copolymer</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ethanol/methanol/propanol/acetone/toluene</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B34-pharmaceutics-11-00021" ref-type="bibr">34</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceutics-11-00021-t003" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-11-00021-t003_Table 3</object-id><label>Table 3</label><caption><p>Examples of microencapsulates and nanoencapsulates by the SFEE process.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Ingredient</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coating Material</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Particle Size and Morphology</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Indomethacin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polylactide-<italic>co</italic>-glycolide (PLGA)/Eudragit RS</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;1 &#x000b5;m<break/>Spherical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-pharmaceutics-11-00021" ref-type="bibr">66</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lysozyme</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~0.1&#x02013;1 &#x000b5;m<break/>Spherical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B69-pharmaceutics-11-00021" ref-type="bibr">69</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ketoprofen</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PLGA</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~0.1&#x02013;1 &#x000b5;m<break/>Spherical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B66-pharmaceutics-11-00021" ref-type="bibr">66</xref>,<xref rid="B68-pharmaceutics-11-00021" ref-type="bibr">68</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vitamin E</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polycaprolactone (PCL)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10&#x02013;300 nm<break/>Spherical nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B71-pharmaceutics-11-00021" ref-type="bibr">71</xref>,<xref rid="B72-pharmaceutics-11-00021" ref-type="bibr">72</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Medroxyprogesterone</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Poly(3-hydroxybutirate-<italic>co</italic>-3-hydroxyvalerate)<break/>(PHBV)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~0.1&#x02013;1 &#x000b5;m<break/>Spherical</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B67-pharmaceutics-11-00021" ref-type="bibr">67</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Omega-3-rich fish oil</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PCL</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10&#x02013;10 nm<break/>Spherical nanoparticles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B70-pharmaceutics-11-00021" ref-type="bibr">70</xref>]</td></tr></tbody></table></table-wrap><table-wrap id="pharmaceutics-11-00021-t004" orientation="portrait" position="float"><object-id pub-id-type="pii">pharmaceutics-11-00021-t004_Table 4</object-id><label>Table 4</label><caption><p>Examples of bioproducts encapsulated using the PGSS process.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Active Ingredient</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Coating Material</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Particle Size and Morphology</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Reference</th></tr></thead><tbody><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">&#x003b2;-carotene</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soy lecithin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10&#x02013;500 &#x003bc;m<break/>Agglomerates of partially fused spheres</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B96-pharmaceutics-11-00021" ref-type="bibr">96</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polycaprolactone (PCL)<break/>(CAPA 2403D and CAPA 6100)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAPA 2403D: 110&#x02013;130 &#x003bc;m<break/>CAPA 6100: 270&#x02013;650 &#x003bc;m<break/>Flat or sphere-like particles attached and agglomerated by long filaments of polymer</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B97-pharmaceutics-11-00021" ref-type="bibr">97</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Coffee oil</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Polyethylene Glycol (PEG)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">78 &#x003bc;m<break/>Spherical shapes of various sizes to amorphous shapes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B98-pharmaceutics-11-00021" ref-type="bibr">98</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1"><italic>Cydia pomonella</italic> granulovirus</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Palm oil-based fat: 77%<break/>Lecithin-based surfactant: 9%<break/>Modified titanium oxide and benzophenone derivative UV protectants: 2%</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#x0003c;85 &#x003bc;m<break/>Almost spherical particles were obtained</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B95-pharmaceutics-11-00021" ref-type="bibr">95</xref>]</td></tr><tr><td rowspan="2" align="left" valign="middle" style="border-bottom:solid thin" colspan="1">Lavandin essential oil</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG 9000</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">30&#x02013;100 &#x003bc;m<break/>Spheres and needles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B93-pharmaceutics-11-00021" ref-type="bibr">93</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soy lecithin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4&#x02013;24.8 &#x003bc;m<break/>Dry and fine but aggregated particles</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B94-pharmaceutics-11-00021" ref-type="bibr">94</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Limonene</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Modified starch</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">60&#x02013;90 &#x003bc;m<break/>Spherical shapes with few broken shapes smaller than the others</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B99-pharmaceutics-11-00021" ref-type="bibr">99</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Omega-3 polyunsaturated fatty acids and astaxanthin-rich salmon oil</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PEG 6000</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">67.26&#x02013;165.81 &#x003bc;m<break/>Irregular spherical shapes to amorphous shapes of various sizes</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B100-pharmaceutics-11-00021" ref-type="bibr">100</xref>]</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Quercetin</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Soy lecithin and Pluronic L64<sup>&#x000ae;</sup></td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.138&#x02013;0.158 &#x003bc;m<break/>Complete encapsulation of amorphous quercetin</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B101-pharmaceutics-11-00021" ref-type="bibr">101</xref>]</td></tr></tbody></table></table-wrap></floats-group></article>